

## **Quarterly Information**

**Dimed S.A. Distribuidora de  
Medicamentos**

March 31, 2022

## Contents

### Company Information

Capital Breakdown .....	1
-------------------------	---

### Individual Interim Financial Statements

Statement of financial position - Assets .....	2
Statement of financial position - liabilities and equity .....	3
Statement of profit or loss .....	5
Statement of comprehensive income .....	6
Statement of cash flows (indirect method) .....	7

### Statement of changes in equity

SCE - 01/01/2022 to 03/31/2022 .....	8
SCE - 01/01/2021 to 03/31/2021 .....	9
Statement of value added.....	10

### Consolidated Interim Financial Statements

Statement of financial position - Assets .....	11
Statement of financial position - liabilities and equity .....	12
Statement of profit or loss.....	14
Statement of comprehensive income .....	15
Statement of cash flows (indirect method) .....	16

### Statement of changes in equity

SCE - 01/01/2022 to 03/31/2022 .....	17
SCE - 01/01/2021 to 03/31/2021 .....	18
Statement of value added.....	19
Notes to quarterly information .....	20

### Reports and Representations

Assessments and Declarations/Summary report of the Audit Committee (statutory, provided for in specific CVM regulations) .....	66
Assessments and Declarations/Assessment or summary report, if applicable, of the Audit committee (statutory or not) .....	67
Officers' Representation on Interim Financial Statements .....	68
Independent auditor's review report on quarterly information .....	70

**Company Information / Capital Breakdown**

<b>Number of shares (unit)</b>	<b>Current quarter 03/31/2022</b>
<b>Paid-in Capital</b>	
Common shares	150,377,481
Preferred shares	0
<b>Total</b>	<b>150,377,481</b>
<b>Treasury shares</b>	
Common shares	1,899,157
Preferred shares	0
<b>Total</b>	<b>1,899,157</b>

## Individual Interim Financial Statements / Statement of Financial Position - Assets

(In thousands of reais)

Account Code	Account Description	Current quarter 03/31/2022	Last year 12/31/2021
1	Total assets	2,476,653	2,372,275
1.01	Current assets	1,373,359	1,331,908
1.01.01	Cash and cash equivalents	38,016	51,590
1.01.02	Short-term investments	13,198	116,712
1.01.02.01	Short-term investments measured at fair value through profit or loss	13,198	116,712
1.01.02.01.03	Short-term investments	13,198	116,712
1.01.03	Accounts receivable	423,765	395,486
1.01.03.01	Trade accounts receivable	336,937	321,230
1.01.03.02	Other accounts receivable	86,828	74,256
1.01.04	Inventories	841,876	726,350
1.01.06	Taxes recoverable	56,504	41,770
1.01.06.01	Current taxes recoverable	56,504	41,770
1.01.06.01.01	Income and social contribution taxes recoverable	29,191	11,418
1.01.06.01.02	Other taxes recoverable	27,313	30,352
1.02	Noncurrent assets	1,103,294	1,040,367
1.02.01	Long-term receivables	49,526	52,019
1.02.01.07	Deferred taxes	35,122	35,736
1.02.01.07.01	Deferred income and social contribution taxes	35,122	35,736
1.02.01.09	Receivables from related parties	2,530	4,700
1.02.01.09.02	Receivables from subsidiaries	2,530	4,700
1.02.01.10	Other noncurrent assets	11,874	11,583
1.02.01.10.03	Other taxes recoverable	8,173	7,895
1.02.01.10.04	Judicial deposits	3,487	3,411
1.02.01.10.05	Other assets	214	277
1.02.02	Investments	70,789	64,639
1.02.02.01	Equity Interests	70,789	64,639
1.02.02.01.02	Interests held in subsidiaries	70,789	64,639
1.02.03	Property, plant and equipment	920,741	864,167
1.02.03.01	Property, plant and equipment in operation	375,389	342,936
1.02.03.02	Right of Use - Lease	545,352	521,231
1.02.04	Intangible assets	62,238	59,542
1.02.04.01	Intangible assets	62,238	59,542
1.02.04.01.02	Intangible assets	62,238	59,542

## Individual Interim Financial Statements / Statement of Financial Position - Liabilities and Equity

(In thousands of reais)

Account Code	Account Description	Current quarter 03/31/2022	Last year 12/31/2021
2	Total liabilities	2,476,653	2,372,275
2.01	Current liabilities	865,014	808,056
2.01.01	Social and labor obligations	54,616	50,483
2.01.01.01	Social obligations	12,749	12,544
2.01.01.02	Labor obligations	41,867	37,939
2.01.02	Trade accounts payable	505,621	470,117
2.01.02.01	Trade accounts payable - local	505,621	470,117
2.01.03	Tax obligations	19,176	27,505
2.01.03.01	Federal tax obligations	4,540	6,255
2.01.03.01.01	Income and social contribution taxes payable	2	0
2.01.03.01.02	Other federal tax obligations	4,538	6,255
2.01.03.02	State tax obligations	13,492	20,247
2.01.03.03	Local tax obligations	1,144	1,003
2.01.04	Loans and financing	200,497	189,137
2.01.04.02	Debentures	58,071	54,532
2.01.04.03	Financing through Lease	142,426	134,605
2.01.05	Other obligations	83,529	69,794
2.01.05.02	Other	83,529	69,794
2.01.05.02.01	Dividends and IOE payable	-108	5,701
2.01.05.02.04	Profit sharing payable	4,439	12,158
2.01.05.02.05	Other liabilities	79,198	51,935
2.01.06	Provisions	1,575	1,020
	Provisions for tax, social security, labor and civil contingencies	1,575	1,020
2.01.06.01.05	Other provisions	1,575	1,020
2.02	Noncurrent liabilities	544,670	518,024
2.02.01	Loans and financing	522,883	501,790
2.02.01.02	Debentures	79,286	79,286
2.02.01.03	Financing through Lease	443,597	422,504
2.02.02	Other obligations	6,579	0
2.02.02.02	Other	6,579	0
2.02.02.02.05	Other obligations	6,579	0
2.02.04	Provisions	15,208	16,234
	Provisions for tax, social security, labor and civil contingencies	15,208	16,234
2.02.04.01.01	Provisions for tax contingencies	710	908
2.02.04.01.02	Provisions for social security and labor contingencies	8,498	9,326
2.02.04.01.04	Provisions for civil contingencies	6,000	6,000
2.03	Equity	1,066,969	1,046,195
2.03.01	Paid-in capital	903,552	903,552
2.03.01.01	Capital	903,552	903,552
2.03.02	Capital reserves	-33,243	-33,409
2.03.02.05	Treasury shares	-37,272	-36,680
2.03.02.07	Incentive in connection with shares	4,029	3,271
2.03.04	Income reserves	176,052	176,052
2.03.04.01	Legal reserve	6,764	6,764
2.03.04.07	Tax incentive reserve	131,624	131,624
2.03.04.08	Proposed additional dividend	13,390	13,390
2.03.04.10	Reserve for capital increase	24,274	24,274

**Individual Interim Financial Statements / Statement of Financial Position -  
Liabilities and Equity****(In thousands of reais)**

<b>Account Code</b>	<b>Account Description</b>	<b>Current quarter 03/31/2022</b>	<b>Last year 12/31/2021</b>
2.03.05	Retained earnings/accumulated losses	20,608	0

**Individual Interim Financial Statements / Statement of Profit or Loss****(In thousands of reais)**

Account Code	Account Description	Current YTD 01/01/2022 to 03/31/2022	Last YTD 01/01/2021 to 03/31/2021
3.01	Revenue from Sales and/or Services	895,882	750,994
3.02	Cost of sales and/or services	-625,944	-519,768
3.03	Gross profit (loss)	269,938	231,226
3.04	Operating income/expenses	-242,323	-205,408
3.04.01	Selling expenses	-230,848	-194,358
3.04.02	General and administrative expenses	-23,282	-22,379
3.04.04	Other operating income	5,657	11,592
3.04.06	Equity pickup	6,150	-263
3.05	Income (loss) before finance income (costs) and taxes	27,615	25,818
3.06	Finance income (costs)	-12,361	1,060
3.06.01	Finance income	3,089	9,023
3.06.02	Finance costs	-15,450	-7,963
3.07	Income (loss) before income taxes	15,254	26,878
3.08	Income and social contribution taxes	5,354	-6,597
3.08.01	Current	5,967	-3,822
3.08.02	Deferred	-613	-2,775
3.09	Net income (loss) from continuing operations	20,608	20,281
3.11	Income/loss for the period	20,608	20,281
3.99	Earnings per share (reais / share)		
3.99.01	Basic earnings per share		
3.99.01.01	Registered Common shares	0.14	0.13
3.99.01.02	Registered Preferred shares	0	0.15
3.99.02	Diluted earnings per share		
3.99.02.01	Registered Common shares	0.14	0.13
3.99.02.02	Registered Preferred shares	0	0.15

**Individual Interim Financial Statements / Statement of Comprehensive Income**  
**(In thousands of reais)**

<b>Account Code</b>	<b>Account Description</b>	<b>Current YTD 01/01/2022 to 03/31/2022</b>	<b>Last YTD 01/01/2021 to 03/31/2021</b>
4.01	Net income for the period	20,608	20,281
4.03	Comprehensive income for the period	20,608	20,281



## Individual Interim Financial Statements / Statement of Cash Flows (Indirect Method)

(In thousands of reais)

Account Code	Account Description	Current	Last
		YTD 01/01/2022 to 03/31/2022	YTD 01/01/2021 to 03/31/2021
6.01	Net cash from operating activities	-25,237	-67,443
6.01.01	Cash from operations	64,525	57,597
6.01.01.01	Net income for the period	20,608	20,281
6.01.01.02	Depreciation and amortization	45,756	35,925
6.01.01.03	Provision for contingent liabilities	-1,026	5,521
6.01.01.04	Equity pickup	-6,150	263
6.01.01.05	Cost of permanent asset written off/sold	3,767	437
6.01.01.06	Allowance for expected credit losses	981	770
6.01.01.07	Provision for inventory losses	-76	-244
6.01.01.08	Tax credits from legal proceeding	-4,896	-18,241
6.01.01.09	Interest expenses on loan/financing	3,539	977
6.01.01.10	Deferred income and social contribution taxes	613	2,775
6.01.01.11	Discounts on leases	-2,020	-1,503
6.01.01.13	Interest expenses on leases	9,302	5,301
6.01.01.15	Rendering of service related to legal proceeding	280	1,277
6.01.01.17	Current income and social contribution taxes	-5,967	3,822
6.01.01.18	Stock option plan or share subscription	748	0
6.01.01.20	Other	-934	236
6.01.02	Changes in assets and liabilities	-89,762	-125,040
6.01.02.01	Credits receivable - customers	-17,148	-7,567
6.01.02.02	Inventories	-115,450	-183,079
6.01.02.03	Trade accounts payable	35,224	38,434
6.01.02.05	Taxes, contributions and social obligations	2,296	30,534
6.01.02.06	Judicial deposits	-76	51
6.01.02.07	Other taxes recoverable	-9,272	-1,122
6.01.02.08	Other asset groups	-10,463	9,034
6.01.02.09	Other liability groups	25,652	-11,325
6.01.02.11	Income and social contribution taxes (IRPJ and CSLL) paid	-525	0
6.02	Net cash from investing activities	52,767	60,493
6.02.01	Acquisition of property, plant and equipment	-44,985	-22,345
6.02.02	Acquisition of intangible assets	-7,156	-5,392
6.02.04	Short-term investments	104,908	88,230
6.03	Net cash from financing activities	-41,104	-47,108
6.03.01	Payment of dividends and interest on equity	-5,809	-6,010
6.03.03	Acquisitions of own shares	-582	-12,689
6.03.05	Payments of lease	-34,713	-28,409
6.05	Increase (decrease) in cash and cash equivalents	-13,574	-54,058
6.05.01	Cash and cash equivalents at beginning of period/year	51,590	92,080
6.05.02	Cash and cash equivalents at end of period/year	38,016	38,022

**Individual Interim Financial Statements / Statement of Changes in Equity / SCE - 01/01/2022 to 03/31/2022****(In thousands of reais)**

<b>Account Code</b>	<b>Account Description</b>	<b>Paid-in capital</b>	<b>Capital reserves, options granted and treasury shares</b>	<b>Income reserves</b>	<b>Retained earnings (accumulated losses)</b>	<b>Other comprehensive income (loss)</b>	<b>Equity</b>
5.01	Opening balances	903,552	-33,409	176,052	0	0	1,046,195
5.03	Adjusted opening balances	903,552	-33,409	176,052	0	0	1,046,195
5.04	Capital transactions with shareholders	0	166	0	0	0	166
5.04.04	Treasury shares acquired	0	-582	0	0	0	-582
5.04.09	Fair value of Matching Share plan	0	748	0	0	0	748
5.05	Total comprehensive income	0	0	0	20,608	0	20,608
5.05.01	Net income for the period	0	0	0	20,608	0	20,608
5.07	Closing balances	903,552	-33,243	176,052	20,608	0	1,066,969

**Individual Interim Financial Statements / Statement of Changes in Equity / SCE - 01/01/2021 to 03/31/2021****(In thousands of reais)**

<b>Account Code</b>	<b>Account Description</b>	<b>Paid-in capital</b>	<b>Capital reserves, options granted and treasury shares</b>	<b>Income reserves</b>	<b>Retained earnings (accumulated losses)</b>	<b>Other comprehensive income (loss)</b>	<b>Equity</b>
5.01	Opening balances	912,000	-30,804	129,444	0	0	1,010,640
5.03	Adjusted opening balances	912,000	-30,804	129,444	0	0	1,010,640
5.04	Capital transactions with shareholders	0	-12,689	-2,068	0	0	-14,757
5.04.04	Treasury shares acquired	0	-12,689	0	0	0	-12,689
5.04.07	Interest on equity	0	0	-2,068	0	0	-2,068
5.05	Total comprehensive income	0	0	0	20,281	0	20,281
5.05.01	Net income for the period	0	0	0	20,281	0	20,281
5.07	Closing balances	912,000	-43,493	127,376	20,281	0	1,016,164

**Individual Interim Financial Statements / Statement of Value Added****(In thousands of reais)**

Account Code	Account Description	Current	Last
		YTD 01/01/2022 to 03/31/2022	YTD 01/01/2021 to 03/31/2021
7.01	Revenues	1,012,723	855,084
7.01.01	Sales of goods, products and services	951,008	798,706
7.01.02	Other income	62,695	57,148
7.01.04	Reversal of/Allowance for expected credit losses	-980	-770
7.02	Bought-in inputs	-751,828	-647,820
7.02.01	Costs of goods, products and services sold	-678,474	-570,336
7.02.02	Materials, electric power, third-party services and other expenses	-77,881	-78,028
7.02.03	Loss/recovery of assets	4,527	544
7.03	Gross value added	260,895	207,264
7.04	Retentions	-45,756	-35,981
7.04.01	Depreciation, amortization and depletion	-45,756	-35,981
7.05	Net value added produced	215,139	171,283
7.06	Value added received in transfer	9,587	1,736
7.06.01	Equity pickup	6,150	-263
7.06.02	Finance income	3,437	1,999
7.07	Total value added to be distributed	224,726	173,019
7.08	Distribution of value added	224,726	173,019
7.08.01	Personnel	105,451	83,324
7.08.01.01	Direct compensation	88,144	69,281
7.08.01.02	Benefits	10,057	8,346
7.08.01.03	Unemployment compensation fund (FGTS)	7,250	5,697
7.08.02	Taxes, charges and contributions	78,096	63,628
7.08.02.01	Federal	20,932	25,259
7.08.02.02	State	55,026	37,390
7.08.02.03	Local	2,138	979
7.08.03	Debt remuneration	20,571	5,787
7.08.03.01	Interest	15,808	953
7.08.03.02	Rental	4,763	4,834
7.08.04	Equity remuneration	20,608	20,280
7.08.04.03	Retained profits/loss for the period	20,608	20,280

## Consolidated Interim Financial Statements / Statement of Financial Position - Assets

(In thousands of reais)

Account Code	Account Description	Current quarter 03/31/2022	Last year 12/31/2021
1	Total assets	2,482,438	2,381,060
1.01	Current assets	1,436,783	1,395,084
1.01.01	Cash and cash equivalents	43,319	54,435
1.01.02	Short-term investments	52,614	155,216
1.01.02.01	Short-term investments measured at fair value through profit or loss	52,614	155,216
1.01.02.01.03	Short-term investments	52,614	155,216
1.01.03	Accounts receivable	426,707	399,456
1.01.03.01	Trade accounts receivable	339,142	324,615
1.01.03.02	Other accounts receivable	87,565	74,841
1.01.04	Inventories	853,647	739,036
1.01.06	Taxes recoverable	60,496	46,941
1.01.06.01	Current taxes recoverable	60,496	46,941
1.01.06.01.01	Income and social contribution taxes recoverable	29,640	11,693
1.01.06.01.02	Other taxes recoverable	30,856	35,248
1.02	Noncurrent assets	1,045,655	985,976
1.02.01	Long-term receivables	52,535	51,921
1.02.01.07	Deferred taxes	37,666	36,846
1.02.01.07.01	Deferred income and social contribution taxes	37,666	36,846
1.02.01.09	Receivables from related parties	2,530	3,030
1.02.01.09.03	Receivables from subsidiaries	2,530	3,030
1.02.01.10	Other noncurrent assets	12,339	12,045
1.02.01.10.03	Other taxes recoverable	8,173	7,895
1.02.01.10.04	Judicial deposits	3,952	3,875
1.02.01.10.05	Other assets	214	275
1.02.02	Investments	4	5
1.02.02.01	Equity Interests	4	5
1.02.02.01.05	Other investments	4	5
1.02.03	Property, plant and equipment	930,475	874,106
1.02.03.01	Property, plant and equipment in operation	385,123	352,875
1.02.03.02	Right of Use - Lease	545,352	521,231
1.02.04	Intangible assets	62,641	59,944
1.02.04.01	Intangible assets	62,641	59,944
1.02.04.01.02	Intangible assets	62,641	59,944

## Consolidated Interim Financial Statements / Statement of Financial Position - Liabilities

(In thousands of reais)

Account Code	Account Description	Current quarter 03/31/2022	Last year 12/31/2021
2	Total liabilities	2,482,438	2,381,060
2.01	Current liabilities	869,055	814,974
2.01.01	Social and labor obligations	55,325	51,167
2.01.01.01	Social obligations	12,933	12,749
2.01.01.02	Labor obligations	42,392	38,418
2.01.02	Trade accounts payable	503,177	464,714
2.01.02.01	Trade accounts payable - local	503,177	464,714
2.01.03	Tax obligations	21,469	30,801
2.01.03.01	Federal tax obligations	5,400	7,776
2.01.03.01.01	Income and social contribution taxes payable	514	671
2.01.03.01.02	Other federal tax obligations	4,886	7,105
2.01.03.02	State tax obligations	14,923	22,018
2.01.03.03	Local tax obligations	1,146	1,007
2.01.04	Loans and financing	200,497	189,137
2.01.04.02	Debentures	58,071	54,532
2.01.04.03	Financing through Lease	142,426	134,605
2.01.05	Other obligations	86,464	77,431
2.01.05.02	Other	86,464	77,431
2.01.05.02.01	Dividends and IOE payable	-108	5,701
2.01.05.02.04	Profit sharing payable	4,439	12,211
2.01.05.02.05	Other liabilities	82,133	59,519
2.01.06	Provisions	2,123	1,724
	Provisions for tax, social security, labor and civil contingencies	2,123	1,724
2.01.06.01	contingencies	2,123	1,724
2.01.06.01.05	Other provisions	2,123	1,724
2.02	Noncurrent liabilities	546,414	519,891
2.02.01	Loans and financing	522,883	501,790
2.02.01.02	Debentures	79,286	79,286
2.02.01.03	Financing through Lease	443,597	422,504
2.02.02	Other obligations	6,579	0
2.02.02.02	Other	6,579	0
2.02.02.02.05	Other obligations	6,579	0
2.02.04	Provisions	16,952	18,101
	Provisions for tax, social security, labor and civil contingencies	16,952	18,101
2.02.04.01	contingencies	16,952	18,101
2.02.04.01.01	Provisions for tax contingencies	2,112	2,310
2.02.04.01.02	Provisions for social security and labor contingencies	8,840	9,791
2.02.04.01.04	Provisions for civil contingencies	6,000	6,000
2.03	Consolidated equity	1,066,969	1,046,195
2.03.01	Paid-in capital	903,552	903,552
2.03.01.01	Capital	903,552	903,552
2.03.02	Capital reserves	-33,243	-33,409
2.03.02.05	Treasury shares	-37,272	-36,680
2.03.02.07	Incentive in connection with shares	4,029	3,271
2.03.04	Income reserves	176,052	176,052
2.03.04.01	Legal reserve	6,764	6,764
2.03.04.07	Tax incentive reserve	131,624	131,624
2.03.04.08	Proposed additional dividend	13,390	13,390
2.03.04.10	Reserve for capital increase	24,274	24,274

**Consolidated Interim Financial Statements / Statement of Financial Position -  
Liabilities****(In thousands of reais)**

<b>Account Code</b>	<b>Account Description</b>	<b>Current quarter 03/31/2022</b>	<b>Last year 12/31/2021</b>
2.03.05	Retained earnings/accumulated losses	20,608	0

**Consolidated Interim Financial Statements / Statement of Profit or Loss****(In thousands of reais)**

<b>Account Code</b>	<b>Account Description</b>	<b>Current YTD 01/01/2022 to 03/31/2022</b>	<b>Last YTD 01/01/2021 to 03/31/2021</b>
3.01	Revenue from sales and/or services	901,550	752,338
3.02	Cost of sales and/or services	-626,076	-519,264
3.03	Gross profit (loss)	275,474	233,074
3.04	Operating income/expenses	-249,632	-207,965
3.04.01	Selling expenses	-231,461	-196,312
3.04.02	General and administrative expenses	-23,874	-23,270
3.04.04	Other operating income	5,703	11,617
3.05	Income (loss) before finance income (costs) and taxes	25,842	25,109
3.06	Finance income (costs)	-11,172	1,237
3.06.01	Finance income	4,361	9,300
3.06.02	Finance costs	-15,533	-8,063
3.07	Income (loss) before income taxes	14,670	26,346
3.08	Income and social contribution taxes	5,938	-6,065
3.08.01	Current	5,118	-4,203
3.08.02	Deferred	820	-1,862
3.09	Net income (loss) from continuing operations	20,608	20,281
3.11	Consolidated income (loss) for the period	20,608	20,281
3.11.01	Attributable to Controlling Shareholders	20,608	20,281
3.99	Earnings per share (reais / share)		
3.99.01	Basic earnings per share		
3.99.01.01	Registered Common shares	0.14	0.13
3.99.01.02	Registered Preferred shares	0	0.15
3.99.02	Diluted earnings per share		
3.99.02.01	Registered Common Shares	0.14	0.13
3.99.02.02	Registered preferred shares	0	0.15



**Consolidated Interim Financial Statements/ Statement of Comprehensive Income****(In thousands of reais)**

<b>Account Code</b>	<b>Account Description</b>	<b>Current YTD</b>		<b>Last YTD</b>
		<b>01/01/2022 to 03/31/2022</b>	<b>01/01/2021 to 03/31/2021</b>	
4.01	Consolidated net income for the period	20,608		20,281
4.03	Consolidated comprehensive income for the period	20,608		20,281
4.03.01	Attributable to Controlling Shareholders	20,608		20,281

## Consolidated Interim Financial Statements / Statement of Cash Flows (Indirect Method)

(In thousands of reais)

Account Code	Account Description	Current	Last
		YTD 01/01/2022 to 03/31/2022	YTD 01/01/2021 to 03/31/2021
6.01	Net cash from operating activities	-22,649	-66,908
6.01.01	Cash from operations	66,345	57,921
6.01.01.01	Net income for the period	20,608	20,281
6.01.01.02	Depreciation and amortization	46,019	36,192
6.01.01.03	Provision for contingent liabilities	-1,149	6,358
6.01.01.04	Cost of permanent asset written off/sold	3,840	438
6.01.01.05	Allowance for expected credit losses	981	770
6.01.01.06	Provision for inventory losses	-121	-228
6.01.01.07	Stock option plan or share subscription	748	0
6.01.01.08	Tax credits from legal proceeding	-4,896	-18,241
6.01.01.09	Deferred income and social contribution taxes	-820	1,862
6.01.01.11	Interest expenses on loan/financing	3,539	977
6.01.01.12	Interest expenses on leases	9,302	5,301
6.01.01.15	Other	-1,848	234
6.01.01.17	Rendering of service related to legal proceeding	280	1,277
6.01.01.19	Current income and social contribution taxes	-5,118	4,203
6.01.01.20	Discounts on leases	-2,020	-1,503
6.01.02	Changes in assets and liabilities	-91,994	-124,829
6.01.02.01	Credits receivable - customers	-15,968	-7,023
6.01.02.02	Inventories	-114,490	-184,135
6.01.02.03	Trade accounts payable	38,183	39,035
6.01.02.05	Taxes, contributions and social obligations	1,123	31,934
6.01.02.06	Judicial deposits	-77	52
6.01.02.07	Other taxes recoverable	-8,092	-3,365
6.01.02.08	Other asset groups	-12,288	8,596
6.01.02.09	Other liability groups	20,794	-9,396
6.01.02.11	Income and social contribution taxes (IRPJ and CSLL) paid	-1,179	-527
6.02	Net cash from investing activities	52,637	26,980
6.02.01	Acquisition of property, plant and equipment	-45,084	-22,446
6.02.02	Acquisition of intangible assets	-7,189	-5,398
6.02.03	Short-term investments	104,910	54,824
6.03	Net cash from financing activities	-41,104	-47,108
6.03.01	Payment of dividends and interest on equity	-5,809	-6,010
6.03.04	Payment of lease	-34,713	-28,409
6.03.06	Acquisitions of own shares	-582	-12,689
6.05	Increase (decrease) in cash and cash equivalents	-11,116	-87,036
6.05.01	Cash and cash equivalents at beginning of period/year	54,435	130,107
6.05.02	Cash and cash equivalents at end of period/year	43,319	43,071

## Consolidated Interim Financial Statements / Statement of Changes in Equity - SCE - 01/01/2022 to 03/31/2022

(In thousands of reais)

Account code	Account Description	Paid-in capital	Capital reserves, options granted and treasury shares	Income reserves	Retained earnings (accumulated losses)	Other comprehensive income (loss)	Equity	Noncontrolling interests	Equity Consolidated
5.01	Opening balances	903,552	-33,409	176,052	0	0	1,046,195	0	1,046,195
5.03	Adjusted opening balances	903,552	-33,409	176,052	0	0	1,046,195	0	1,046,195
5.04	Capital transactions with shareholders	0	166	0	0	0	166	0	166
5.04.04	Treasury shares acquired	0	-582	0	0	0	-582	0	-582
5.04.09	Fair value of Matching Share plan	0	748	0	0	0	748	0	748
5.05	Total comprehensive income	0	0	0	20,608	0	20,608	0	20,608
5.05.01	Net income for the period	0	0	0	20,608	0	20,608	0	20,608
5.07	Closing balances	903,552	-33,243	176,052	20,608	0	1,066,969	0	1,066,969

## Consolidated Interim Financial Statements / Statement of Changes in Equity - SCE - 01/01/2021 to 03/31/2021

(In thousands of reais)

Account code	Account Description	Paid-in capital	Capital reserves, options granted and treasury shares	Income reserves	Retained earnings (accumulated losses)	Other comprehensive income (loss)	Equity	Noncontrolling interests	Equity Consolidated
5.01	Opening balances	912,000	-30,804	129,444	0	0	1,010,640	0	1,010,640
5.03	Adjusted opening balances	912,000	-30,804	129,444	0	0	1,010,640	0	1,010,640
	Capital transactions with								
5.04	shareholders	0	-12,689	-2,068	0	0	-14,757	0	-14,757
5.04.04	Treasury shares acquired	0	-12,689	0	0	0	-12,689	0	-12,689
5.04.07	Interest on equity	0	0	-2,068	0	0	-2,068	0	-2,068
5.05	Total comprehensive income	0	0	0	20,281	0	20,281	0	20,281
5.05.01	Net income for the period	0	0	0	20,281	0	20,281	0	20,281
5.07	Closing balances	912,000	-43,493	127,376	20,281	0	1,016,164	0	1,016,164

**Consolidated Interim Financial Statements / Statement of Value Added****(In thousands of reais)**

Account Code	Account Description	Current YTD		Last YTD
		01/01/2022 to 03/31/2022	01/01/2021 to 03/31/2021	01/01/2021
7.01	Revenues	1,019,279		852,528
7.01.01	Sales of goods, products and services	957,521		799,802
7.01.02	Other income	62,738		53,496
7.01.04	Reversal of/Allowance for expected credit losses	-980		-770
7.02	Bought-in inputs	-752,366		-645,878
7.02.01	Costs of goods, products and services sold	-678,325		-565,990
	Materials, electric power, third-party services and other expenses			
7.02.02		-78,568		-80,432
7.02.03	Loss/recovery of assets	4,527		544
7.03	Gross value added	266,913		206,650
7.04	Retentions	-46,019		-36,242
7.04.01	Depreciation, amortization and depletion	-46,019		-36,242
7.05	Net value added produced	220,894		170,408
7.06	Value added received in transfer	4,721		2,247
7.06.02	Finance income	4,721		2,247
7.07	Total value added to be distributed	225,615		172,655
7.08	Distribution of value added	225,615		172,655
7.08.01	Personnel	106,094		83,937
7.08.01.01	Direct compensation	88,710		69,731
7.08.01.02	Benefits	10,099		8,401
7.08.01.03	Unemployment compensation fund (FGTS)	7,285		5,805
7.08.02	Taxes, charges and contributions	78,519		63,818
7.08.02.01	Federal	21,107		25,775
7.08.02.02	State	55,231		36,992
7.08.02.03	Local	2,181		1,051
7.08.03	Debt remuneration	20,394		4,620
7.08.03.01	Interest	15,893		1,011
7.08.03.02	Rental	4,501		3,609
7.08.04	Equity remuneration	20,608		20,280
7.08.04.02	Dividends	20,608		20,280

# Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

## 1. Operations

Dimed S.A. Distribuidora de Medicamentos or “Dimed” and its subsidiaries (jointly referred to as the “Company”), with head office in the city of Eldorado do Sul, state of Rio Grande do Sul, is primarily engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. To support its sales, the Company has distribution centers in the states of Rio Grande do Sul, Paraná and Espírito Santo, in addition to 527 stores distributed among the states of Rio Grande do Sul, Santa Catarina, Paraná and São Paulo.

The parent company is a corporation listed on B3 S.A. - BRASIL, BOLSA, BALCÃO (ticker symbol PNVL3).

Subsidiary Laboratório Industrial Farmacêutico Lifar Ltda. operates in the industrial segment, producing a wide range of products in the cosmetics, food, medicine and outsourced production segments. It is responsible for most of the production of the own brand product line from the Company’s pharmacy chain and parent company of Empresa Lifar Distribuidora de Produtos Farmacêuticos Ltda., which is engaged in the distribution of the products produced.

Subsidiary Dimesul Gestão Imobiliária Ltda. is engaged in the purchase, sale, intermediation, subdivision, lease, rent, management and administration of own or third-party properties, with a view to centralizing and optimizing the management of the Company’s properties.

In the 12-month period, the Company opened the total of 68 stores, 15 of which in the first quarter of 2022. Over this quarter, it also closed 2 stores and 3 stores were transferred, since they had a low capacity to improve performance in a post-pandemic scenario. The Company closed the first quarter with a total of 527 stores in operation.

The issue of these individual and consolidated interim financial statements was authorized by the Company’s Board of Directors on May 11, 2022.

### Impacts of COVID-19

In 1Q22, the Company continued to assess the impacts of COVID-19 on its operations and identified no significant increase in the credit risk of trade accounts receivable that could entail the reassessment of its assumptions relating to the allowance. Regarding the impairment of its assets, the Company also detected no material adverse impact on its cash and cash equivalents, inventories and permanent assets.

The actions of the Brazilian public authorities in the face of the effects of the pandemic continue to be monitored, but none of them has affected the Company’s operations or sales, in the management’s understanding. The care protocols for the Retail and Logistics operational teams continue to be applied, as well as the distancing rules within the corporate framework, which reduces the risk of contamination in shared spaces.

# **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

## **1. Operations (Continued)**

### Impacts of COVID-19 (Continued)

In May 2020, the IASB issued amendments to IFRS 16 - Leases referring to COVID-19-related benefits granted to lessees under lease agreements. On July 7, 2020, the Brazilian SEC (CVM), through Rule No. 859/20, approved amendments to Accounting Pronouncement CPC 06 (R2) - Leases, which is equivalent to the IFRS at issue.

As a practical expedient, the lessee may choose not to assess whether a benefit granted in a lease, related to COVID-19, is a modification of the lease agreement and thus account for the resulting changes in lease payments in profit or loss for the period. The Company applied the practical expedient to all benefits granted in lease agreements in line with the requirements of CVM Rule No. 859/20 (Note 28).

Furthermore, the Company reinforced the framework of its distribution centers, delivery stores and call center. It also invested in a new distribution center in the city of São José dos Pinhais (state of Paraná), which started operations in January 2021, and opened three more mini distribution centers in strategic markets to meet this growing demand for sales in the online format: i) Canoas (state of Rio Grande do Sul) opened in August 2020; ii) São Paulo (state of São Paulo) opened in December 2020; and iii) Caxias do Sul (state of Rio Grande do Sul) opened in January 2021.

## **2. Summary of significant accounting policies**

Significant accounting policies used in preparing these individual and consolidated interim financial statements are described below. These policies have been consistently applied for all years presented.

### **2.1. Basis of preparation and presentation of individual and consolidated interim financial statements**

The Company's interim financial information, contained in the Quarterly Information Form (ITR), for the quarter ended March 31, 2022 was prepared and is being presented in accordance with CPC 21 (R1) - Interim Financial Reporting, issued by Brazil's Financial Accounting Standards Board - FASB ("CPC") and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR).

Company management understands that all significant information related to the interim financial statements is disclosed and corresponds to the information used to manage the Company's operations.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 2. Summary of significant accounting policies (Continued)

#### 2.1. Basis of preparation and presentation of individual and consolidated interim financial statements (Continued)

The interim financial statements were prepared by the Company to update the users on the relevant information presented for the period and should be analyzed together with the whole financial statements for the year ended December 31, 2021.

The preparation of interim financial statements is based on historical cost, except for financial instruments measured at fair value, as per Note 5, which require the use of certain accounting estimates that affect the balances of asset, liability and profit or loss accounts, as well as the exercise of judgment by management members in the process of applying the Company's accounting policies. The most significant effects on the book accounts that involve the use of estimates or that require more complex judgments are disclosed in Note 3.

In preparing these interim financial statements, the Company followed the same accounting policies and calculation methods as were applied in the individual and consolidated financial statements as at December 31, 2021. The Company adopted all standards, revised standards and interpretations issued by Brazil's FASB ("CPC"), IASB and regulators that were effective as at March 31, 2022.

The presentation of the individual and consolidated Statement of Value Added (SVA) is required by the Brazilian Corporation Law and by the accounting practices adopted in Brazil applicable to publicly-held companies. IFRS do not require presentation of this statement. As a result, under IFRS, this statement is presented as supplementary information, without prejudice to the set of financial statements.

The consolidated interim financial statements include the operations of the Company and of the following subsidiaries:

Company	Activity	Direct equity interest	
		2022	2021
Laboratório Industrial Farmacêutico Lifar Ltda.	Production of cosmetics, food, medicines and outsourced production.	99.99%	99.99%
Dimesul Gestão Imobiliária Ltda.	Management and administration of own and/or third-party properties.	99.99%	99.99%

  

Company	Activity	Indirect equity interest	
		2022	2021
Lifar Distribuidora de Produtos Farmacêuticos Ltda.	Pharmaceutical products distributor.	99.97%	99.97%



## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### **2. Summary of significant accounting policies (Continued)**

#### **2.1. Basis of preparation and presentation of the individual and consolidated financial statements (Continued)**

These consolidated interim financial statements are prepared in accordance with the consolidation practices and applicable legal provisions. The accounting practices adopted by the Subsidiary were consistently applied and are consistent with the ones adopted by the Company. Where applicable, all transactions, balances, revenues and expenses between the Subsidiary and the Company are fully eliminated from the consolidated interim financial statements.

The financial statement period of the subsidiaries included in the consolidation coincides with that of the Parent Company and the accounting policies have been consistently applied in the consolidated companies and are consistent with those used in prior year.

Income for the year is fully attributed to the controlling interests given that equity interest held by noncontrolling interests corresponds to 0.01% of the consolidated.

### **3. Significant accounting estimates and judgments**

In preparing these interim financial statements, it is necessary to use estimates to account for certain assets, liabilities and other transactions. Therefore, the interim financial statements include various estimates referring to the allowance for expected credit losses, provision for inventory losses, assessment of the useful lives of property, plant and equipment, loyalty program, provisions required for contingent liabilities and determination of provisions for income tax. Since management's judgment involves determining estimates related to the likelihood of future events, actual results may differ from these estimates. The estimates considered to be more critical by management, which may have significant effects on the accounting balances, are described below:

#### a) Provision for inventory losses

The provision for inventory losses is estimated based on the inventories of stores and distribution centers, whose maturity dates are close to the expiration date, and deemed sufficient by management to cover the risk of loss on these inventories. These amounts are stated in Note 8. The Company monthly evaluates and writes off items that are already past due and damaged.

## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### **3. Significant accounting estimates and judgments (Continued)**

b) Allowance for expected credit losses

The allowance for expected credit losses is based on certain assumptions and involves management's judgment, consistent with the accounting policies disclosed in Note 2.5.4 to the financial statements as at December 31, 2021. The amounts may be found in Note 7.

c) Provisions for tax, civil and labor contingencies

The estimates to set up the provisions for contingencies are analyzed by management, based on the opinion of the Company's lawyers, where factors such as the hierarchy of laws, available case law, most recent court decisions and their relevance in the legal system are considered. The realization of these estimates may result in amounts different from those recorded in the accounts depending on the outcome of each legal or administrative proceeding.

d) Contractual payments

The estimates for the accounting recognition of negotiations for payments are based on the transactions with suppliers, consistently with the accounting practices disclosed in Note 2.8 to the financial statements as at December 31, 2021. These amounts may be verified in Note 27, under "Reimbursement of capital contribution costs".

e) Income taxes

Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Given the wide tax legislation as well as the long-term nature and complexity of existing contractual agreements, differences between actual results and the assumptions made, or future changes in such assumptions, could require future adjustments to tax income and expenses already recorded.

When determining current and deferred income tax, the Company takes into consideration the impact of uncertain tax positions. The Company understands that the provision for income tax is adequate based on the assessment of various factors, including interpretations of tax laws and the opinion of its legal advisors.

The Company sets up provisions, based on reliable estimates, for possible consequences from audits by tax authorities of the respective jurisdictions in which it operates. The amount of these provisions is based on various factors, such as past tax audit experience and differing interpretations of tax regulations by the taxable entity and by the competent tax authority. These different interpretations may arise in a wide range of issues, depending on the prevailing conditions in the respective domicile of the Company.

## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### **3. Significant accounting estimates and judgments (Continued)**

#### e) Income taxes (Continued)

Significant judgment from management is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits, together with future tax planning strategies.

The Company has ICMS tax benefits and incentives in certain states where it operates. These incentives were considered an investment grant under the terms of Complementary Law No. 160/2017. These incentives, when calculated, are allocated to the Tax Incentive Reserve (Note 22). Incentive-related resources are not distributed as dividends. In compliance with ICPC 22 (IFRIC 23), management carried out, assisted by its legal advisors, an analysis of the acceptability of the tax treatment described, concluding that it is likely that the tax authority will accept it.

#### f) Discount rate of IFRS 16/CPC 06 (R2)

Estimates for determining the discount rate are based on assumptions, as described in Note 20.

### **4. Financial risk management**

#### **4.1. Financial risk factors**

The Company's activities expose it to various financial risks: market risk (including fair value interest rate risk and cash flow interest rate risk), credit risk, liquidity risk and currency risk. The Company's global risk management program is concentrated in the unpredictability of the financial markets and aims to minimize potential adverse effects on the Company's financial performance.

Risk management is conducted by the Company's Controllership. The Controllership, through the Treasury Department, identifies, evaluates and hedges the Company against any financial risks in cooperation with the Company's operational units. The Board of Directors establishes global risk management principles, including for specific areas, such as interest rate risk, credit risk, use of nonderivative financial instruments and investment of cash surplus.

# Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

## 4. Financial risk management (Continued)

### 4.1. Financial risk factors (Continued)

#### a) Market risk

##### *Interest rate risk*

The Company's interest rate risk arises from long-term borrowings and cash surplus invested in floating rate notes, such as Bank Deposit Certificates (CDBs). Borrowings and investments at variable rates expose Dimed to the cash flow interest rate risk. Borrowings and investments issued at fixed rates expose Dimed to the fair value interest rate risk. At March 31, 2022 and December 31, 2021, Dimed's borrowings and investments at variable and fixed rates were kept in Brazilian reais.

Dimed analyzes its exposure to interest rate in a dynamic manner. Scenarios are simulated, taking into consideration the refinancing, renewal of existing positions and alternative financing, as well as new investment possibilities for cash surplus. Based on these scenarios, Dimed defines a reasonable interest rate change and calculates its impact on profit or loss. The scenarios are prepared only for liabilities and assets representing key interest-bearing positions.

##### *Sensitivity analysis*

The sensitivity analysis of interest rates on financial instruments of the Company and its subsidiaries is presented below, which describes the risks that may generate significant variations, with the most probable scenario (scenario I) according to management's assessment, considering a 12-month period, followed by two other scenarios. Scenario II corresponds to a possible 25% variation in interest rates and scenario III corresponds to a 50% variation in interest rates.

Rate	Transaction	Probable scenario (Scenario I)	Scenario II (25% variation)	Scenario III (50% variation)
CDI - %	Decrease	11.75	8.81	5.88
CDI - %	Increase	11.75	14.69	17.63
	Short-term investments - fixed income	9,934	7,451	4,967
	Borrowings	16,139	20,174	24,209

## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### **4. Financial risk management (Continued)**

#### **4.1. Financial risk factors (Continued)**

b) Credit risk

Credit risk is managed on a corporate-level basis and arises from cash and cash equivalents, as well as credit exposures with customers, both legal entities and individuals, including outstanding receivables and repurchase agreements. For banks and financial institutions, only notes of entities that have compensating transactions with the Company are accepted. The Credit Analysis area assesses the customer creditworthiness, taking into consideration its financial position, past experience and other factors. Individual risk limits are established based on internal or external ratings, according to the limits determined by the Board of Directors and management. The use of credit limits is regularly monitored by management. Sales to customers of retail branches are settled in local currency, check, agreements or by means of the main credit cards existing in the market.

The carrying amount of financial assets represents the maximum credit risk exposure.

Cash flow projection is carried out on a corporate-level basis through the treasury department, based on information provided by the operating units and the procurement department. The Treasury Department monitors the forecasts of the Company's liquidity requirements to ensure that it has cash sufficient to meet its operating needs. It also keeps sufficient margin of credit facilities, under repurchase agreements, available for the Company at any time, so that it does not exceed limits or breach loan agreement clauses (where applicable) in any of its credit facilities. Such projection takes into consideration the Company's debt financing plans, covenant compliance, compliance with internal ratio targets of the statement of financial position and, if applicable, external regulatory or legal requirements - for instance, currency restrictions.

c) Liquidity risk

Any cash surplus held by the operational entities, in addition to the amount required for working capital management purposes, is managed by the treasury department, which invests the cash surplus in short-term investments, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient margins as determined by the above-mentioned forecasts. At March 31, 2022, the Company had short-term investments amounting to R\$13,198 in the Individual and R\$52,614 in the consolidated interim financial statements, which generated cash inflows to manage liquidity risk.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 4. Financial risk management (Continued)

#### 4.1. Financial risk factors (Continued)

##### c) Liquidity risk (Continued)

The table below analyzes the Company's nonderivative financial liabilities, by maturity date, corresponding to the remaining period in the statement of financial position up to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

	Consolidated				
	Contractual cash flow	Within 1 year	From 1 to 2 years	From 3 to 5 years	Above 5 years
<b>At March 31, 2022</b>					
Trade accounts payable	503,177	503,177	-	-	-
Leases	586,023	142,426	130,997	194,960	117,640
Debenture - Banco Bradesco	149,267	59,297	21,103	68,867	-
<b>Total</b>	<b>1,238,467</b>	<b>704,900</b>	<b>152,100</b>	<b>263,827</b>	<b>117,640</b>

	Consolidated				
	Contractual cash flow	Within 1 year	From 1 to 2 years	From 3 to 5 years	Above 5 years
<b>At December 31, 2021</b>					
Trade accounts payable	464,714	464,714	-	-	-
Leases	557,109	134,605	124,768	185,690	112,046
Debenture - Banco Bradesco	145,653	55,683	21,103	68,867	-
<b>Total</b>	<b>1,167,476</b>	<b>655,002</b>	<b>145,871</b>	<b>254,557</b>	<b>112,046</b>

#### 4.2. Capital Management

The Company's objectives in managing its capital are to safeguard its ability to continue as a going concern in order to provide returns for its shareholders and benefits for other stakeholders as well as to maintain an optimal target capital structure to reduce the cost of capital.

To maintain or adjust its capital structure, the Company may revise the policy for payment of dividends, return capital to shareholders, issue new shares, or sell assets to reduce its indebtedness, for instance. In line with other companies in the sector, the Company monitors capital based on the financial leverage ratio. This ratio corresponds to the net debt divided by total capital. Net debt, in its turns, corresponds to total loans (including short and long-term loans, as stated in the consolidated statement of financial position), deducted from cash and cash equivalents. Total capital is calculated through the sum of equity, as stated in the consolidated statement of financial position, plus net debt.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 4. Financial risk management (Continued)

#### 4.2. Capital management (Continued)

The Company's business strategy is to maintain its net financial indebtedness, compared to the sum of net financial debt and equity, at low levels. Financial leverage ratios at March 31, 2022 and December 31, 2021 are summarized as follows:

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Total loans (Note 17)	137,357	133,818	137,357	133,818
Less:				
Cash and cash equivalents (Note 6)	(38,016)	(51,590)	(43,319)	(54,435)
Short-term investments (Note 6)	(13,198)	(116,712)	(52,614)	(155,216)
Net debt - A	(86,143)	(34,484)	(41,424)	(75,833)
<b>Total equity</b>	<b>1,066,969</b>	<b>1,046,195</b>	<b>1,066,969</b>	<b>1,046,195</b>
Total capital - B	980,826	1,011,711	1,025,545	970,362
Ratio - % - A/B (*)	-8.78	-3.41	-4.04	-7.81

### 5. Financial instruments by category

At March 31, 2022 and December 31, 2021, financial assets are classified as follows:

	03/31/2022			
	Individual		Consolidated	
	Amortized cost	Fair value through profit or loss	Amortized cost	Fair value through profit or loss
Cash and cash equivalents	-	38,016	-	43,319
Short-term investments	-	13,198	-	52,614
Trade and other accounts receivable	423,765	-	426,707	-
	<b>423,765</b>	<b>51,214</b>	<b>426,707</b>	<b>95,933</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 5. Financial instruments by category (Continued)

	12/31/2021			
	Individual		Consolidated	
	Amortized cost	Fair value through profit or loss	Amortized cost	Fair value through profit or loss
Cash and cash equivalents	-	51,590	-	54,435
Short-term investments	-	116,712	-	155,216
Trade and other accounts receivable	395,486	-	399,456	-
	<b>395,486</b>	<b>168,302</b>	<b>399,456</b>	<b>209,651</b>

#### Classification of financial liabilities

	Individual		Consolidated	
	Amortized cost		Amortized cost	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Trade accounts payable	<b>505,621</b>	470,117	<b>503,177</b>	464,714
Loans and financing	<b>137,357</b>	133,818	<b>137,357</b>	133,818
Lease obligations	<b>586,023</b>	559,109	<b>586,023</b>	559,109
	<b>1,229,001</b>	1,163,044	<b>1,226,557</b>	1,157,641

Fair values are determined based on market price quotations, when available, or in their absence, the present value of expected cash flows. The fair values of cash and cash equivalents, trade and other accounts receivable, and trade accounts payable are equivalent to their carrying amounts.

The estimated fair value of loans and financing in the individual and consolidated statements as at March 31, 2022 was R\$134,079, calculated at current market rates, considering their nature, term and risks, can be compared with their carrying amount of R\$137,357.

#### Fair value hierarchy

The Company applies CPC 40 (R1) to financial instruments, which requires the disclosure of fair value measurements based on the following hierarchy levels:

*Level 1:* prices quoted (unadjusted) in active markets for identical assets or liabilities;

*Level 2:* other techniques for which all inputs that have a material effect on the recorded fair value are observable, either directly or indirectly;

*Level 3:* techniques using inputs that have a material effect on the fair value recorded that are not based on observable market data.



## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 5. Financial instruments by category (Continued)

The Company's financial instruments are measured using the Level 2 valuation technique. There were no transfers between levels 1, 2 and 3 until March 31, 2022.

### 6. Cash and cash equivalents and marketable securities

#### Cash and cash equivalents

	Average rate (p.a.%)	Individual		Consolidated	
		03/31/2022	12/31/2021	03/31/2022	12/31/2021
Cash on hand (retail branches)	-	4,557	4,634	4,575	4,654
Short-term bank deposits	-	1,927	9,521	2,171	10,661
Short-term investments - fixed income (*)	87% of CDI	31,532	37,435	36,573	39,120
		<b>38,016</b>	51,590	<b>43,319</b>	54,435

(\*) Short-term investments mostly refer to Bank Deposit Certificates (CBD) and repurchase agreements, remunerated at a CDI percentage. Information on investment liquidity is detailed in Note 4.

#### Marketable securities

	Average rate (p.a.%)	Individual		Consolidated	
		03/31/2022	12/31/2021	03/31/2022	12/31/2021
Boutique investment fund		13,198	116,712	52,614	155,216
		<b>13,198</b>	116,712	<b>52,614</b>	155,216

Short-term investments by type are broken down as follows:

Type	Consolidated	
	03/31/2022	12/31/2021
Investment funds	5,509	5,364
Bank Deposit Certificate (CDB)	642	4,062
Debentures	16,475	27,880
Time deposits with special guarantee (DPGE)	1,079	2,103
Financial Bills	25,103	71,600
Financial Treasury Bills ("LFT")	-	15,978
National Treasury Notes ("LTN-O")	3,806	28,229
	<b>52,614</b>	155,216

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 6. Cash and cash equivalents and marketable securities (Continued)

#### Marketable securities (Continued)

GD FIM Crédito Privado is a private credit fixed income fund under the management, administration and custody of BRAM - Bradesco Asset Management S.A. DTVM. The investment fund does not have significant financial obligations. These are limited to asset management fees, custody fees, audit fees and expenses. The fund is exclusively for the benefit of the Company and, therefore, the financial investment in the investment fund in which the Company holds an exclusive interest has been consolidated.

### 7. Trade accounts receivable

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Trade accounts receivable	83,939	67,661	86,144	71,046
Accounts receivable - credit cards	260,351	259,481	260,351	259,481
Provision for financial charges	(1,011)	(551)	(1,011)	(551)
Allowance for expected credit losses	(6,342)	(5,361)	(6,342)	(5,361)
Trade accounts receivable, net	<b>336,937</b>	321,230	<b>339,142</b>	324,615

Aging list of trade accounts receivable:

	03/31/2022	12/31/2021
<b>Falling due</b>		
Within 30 days	172,826	158,431
31 to 60 days	85,714	77,988
61 to 90 days	36,275	37,501
91 to 120 days	19,273	17,788
121 to 150 days	9,964	10,829
151 to 180 days	5,229	5,291
Above 180 days	5,589	4,964
	<b>334,870</b>	312,792
<b>Overdue</b>		
Within 30 days	2,259	3,203
31 to 90 days	799	698
Above 90 days	6,362	10,449
	<b>9,420</b>	14,350
Provision for financial charges	(1,011)	(551)
Allowance for expected credit losses	(6,342)	(5,361)
<b>Total Individual</b>	<b>336,937</b>	321,230
Trade accounts receivable (Lifar) - Falling due	1,764	2,708
Trade accounts receivable (Lifar) - Overdue	441	677
<b>Total - Consolidated</b>	<b>339,142</b>	324,615

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 7. Trade accounts receivable (Continued)

Changes in provision for impairment of accounts receivable are as follows:

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Balance at beginning of period	(5,361)	(4,982)	(5,361)	(4,982)
Supplemental provision	(983)	(1,703)	(983)	(1,703)
Provision amounts written off	2	1,324	2	1,324
	<b>(6,342)</b>	<b>(5,361)</b>	<b>(6,342)</b>	<b>(5,361)</b>

Recognition and derecognition of the allowance for expected credit losses were recorded in the statement of profit or loss for the year as "Net losses on receivables". The amounts charged to the allowance account are usually written off when there is no expectation of recovery of funds.

The maximum exposure to credit risk at the reporting date is the carrying amount of each class of the abovementioned receivables.

As regards the possible impacts of COVID-19, Dimed detected no significant risk of loss in trade receivables, since the customer portfolio comprises mostly credit card companies. Therefore, management assessed and concluded that there was no significant increase in credit risk in relation to Trade accounts receivable that could justify any adjustment in the allowance for expected credit losses, as well as the need, at this time, for any additional disclosure on the impact of the Covid-19 pandemic in relation to the Company's receivables.

### 8. Inventories

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Goods for resale	836,919	720,690	838,258	722,775
Finished products	-	-	3,757	4,652
Raw materials	-	-	2,526	1,897
Consumables/storeroom supplies	5,357	6,136	9,634	10,361
(-) Provision for inventory losses	(400)	(476)	(528)	(649)
	<b>841,876</b>	<b>726,350</b>	<b>853,647</b>	<b>739,036</b>

#### Provision for inventory losses

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Opening balance	(476)	(287)	(649)	(408)
Supplemental provision	(693)	(1,177)	(821)	(1,506)
Provision amounts written off	769	988	942	1,265
Balance at end of year	<b>(400)</b>	<b>(476)</b>	<b>(528)</b>	<b>(649)</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 9. Income and social contribution taxes recoverable

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Corporate Income Tax - IRPJ	23,895	10,679	24,262	10,915
Social Contribution Tax on Net Profit - CSLL	5,296	739	5,378	778
	<b>29,191</b>	11,418	<b>29,640</b>	11,693

The Company closed the proceeding referring to the res judicata decision on the lawsuit that challenged the exclusion of the matching ICMS credits from the IRPJ and CSLL tax bases, determining that the matching tax credits should not be included in the IRPJ and CSLL tax bases, therefore recognizing the right to the credit. Accordingly, Dimed calculated and recorded the credits in the second quarter of 2021, in the total amount of R\$17,708, of which R\$12,167 refer to principal and R\$5,542 refer to monetary restatement. In the third and fourth quarters of 2021, part of this amount was offset, remaining recorded credits in the amount of R\$4,692, of which R\$3,346 refer to principal and R\$1,346 refer to monetary restatement. The Company prepared the calculations supported by a specialized consulting firm. In the third quarter of 2022, the restated amount is R\$4,740, of which R\$3,346 refer to principal and R\$1,394 refer to monetary restatement, to be offset throughout the period. The proceeding related to this tax credit became final and unappealable on April 23, 2021, and the Brazilian IRS (SRF) authorized it on July 2, 2021. Management expects the tax credits of parent company Dimed will be offset within 12 months.

In the first quarter of 2022, the Company carried out a survey and determined tax credits relating to the res judicata decision on the lawsuit in which it claimed the non-levy of IRPJ and CSLL on the reimbursed amounts referring to insurance indemnity, thus recognizing the right to the credit. Accordingly, Dimed calculated and recorded credits in the total amount of R\$16,862, of which R\$12,811 refer to principal and R\$4,051 refer to monetary restatement, arising from the res judicata decision on the lawsuit. The Company filed a request to validate the credits with the Brazilian IRS (SRF), which was approved on March 31, 2022, and expects that these credits will be offset within 12 months.

On September 24, 2021, the Federal Supreme Court of Brazil ("STF") ruled for the non-levy of IRPJ and CSLL on the amounts related to the Brazil's Central Bank benchmark rate (SELIC), which are received by the taxpayer due to unduly paid tax amounts. The decision is grounded on the understanding that the arrears interest and monetary restatement, due to their indemnity nature, do not reflect an equity increase, as their function is to repair the monetary losses suffered over the period of discussion of the unduly paid tax amounts. On June 8, 2010, the Company filed a lawsuit challenging the matter, which, considering its current stage, does not yet have all the necessary requirements, in light of IAS 37/CPC 25, for recording any income and social contribution tax credits.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 10. Taxes recoverable

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
<b>Current</b>				
State Value Added Tax - ICMS	3,535	3,143	3,863	3,483
Contribution Tax on Gross Revenue for Social Integration Program - PIS	1,078	1,039	1,083	1,044
Contribution Tax on Gross Revenue for Social Security Financing - COFINS	4,968	4,788	4,990	4,813
Credit relating to the exclusion of the ICMS from the PIS and COFINS tax base	17,707	21,382	20,853	25,866
Other	25	-	67	42
	<b>27,313</b>	<b>30,352</b>	<b>30,856</b>	<b>35,248</b>
<b>Noncurrent</b>				
State Value Added Tax - ICMS	8,173	7,895	8,173	7,895
	<b>8,173</b>	<b>7,895</b>	<b>8,173</b>	<b>7,895</b>

#### ICMS on PIS and COFINS tax base

In January 2021, the Company closed the proceeding referring to the res judicata decision on the lawsuits that challenged the exclusion of the ICMS from the PIS and COFINS tax base, determining that the ICMS does not make up the PIS and COFINS tax base, therefore recognizing the right to the credit. With regard to the ICMS to be excluded, the decision recognizes that “the plaintiff may exclude from the PIS and COFINS tax base the ICMS recorded in the sales invoices of its establishment, in order to, once adjusted the new tax base, determine the amounts unduly paid”.

Considering that the Company’s lawsuits were filed in 2006, the amounts recoverable were calculated retrospectively to the accrual period of November 2001, since the decision of the Federal Court of Appeals of the 4th Chapter determined a 5-year statute barring period, considering that the lawsuit was filed after the effectiveness of Complementary Law No. 118/2005.

The calculations were prepared with the support of a specialized consulting firm, based on the sales invoices for the entire year, reconciled with the information from accessory obligations. Accordingly, Dimed calculated and recorded the credits in 2021, in the total amount of R\$20,954. At December 31, 2021, these credits totaled R\$21,382, of which R\$12,325 refer to principal and R\$9,057 refer to monetary restatement. In the third quarter of 2022, part of this amount was offset, remaining recorded the balance of R\$17,707, of which R\$10,921 refer to principal and R\$6,786 refer to monetary restatement as of March 31, 2022.

In the last quarter of 2020, subsidiary LIFAR was also awarded a res judicata decision on the lawsuit to exclude the ICMS from the PIS and COFINS tax base, based on the ICMS recorded in sales invoices, therefore, the amount of R\$5,850 was determined and recorded in 2020. At March 31, 2021, the balance of these credits was R\$3,146 (R\$4,484 at December 31, 2021). Management expects Dimed’s and its subsidiaries’ tax credits will be offset within 12 months.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 11. Investments in subsidiaries

Investments in subsidiaries are as follows:

	03/31/2022							
	Capital	Units of interest held (unit)	(%) Equity interest	Equity	Net income for the period	Opening balance at January 1	Equity pickup	Total investments
Laboratório Industrial Farmacêutico Lifar Ltda.	500	499,999	99.99%	29,410	1,505	26,750	1,299	28,049
Dimesul Gestão Imobiliária Ltda.	8,978	19,999	99.99%	42,740	4,851	37,889	4,851	42,740
						<u>64,639</u>	<u>6,150</u>	<u>70,789</u>

	12/31/2021							
	Capital	Units of interest held (unit)	(%) Equity interest	Equity	Net income (loss) for the period	Opening balance at January 1	Equity pickup	Total investments
Laboratório Industrial Farmacêutico Lifar Ltda.	500	499,999	99.99%	27,905	(3,042)	29,538	(2,788)	26,750
Dimesul Gestão Imobiliária Ltda.	8,978	19,999	99.99%	37,890	2,521	35,368	2,521	37,889
						<u>64,906</u>	<u>(267)</u>	<u>64,639</u>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 11. Investment in subsidiaries (Continued)

Information related to the subsidiaries is shown below:

<b>Subsidiaries - 2022</b>	<b>03/31/2022</b>			
	<b>Control</b>	<b>Assets</b>	<b>Liabilities</b>	<b>Equity</b>
Laboratório Industrial Farmacêutico Lifar Ltda.	Direct equity interest	<b>40,322</b>	<b>10,912</b>	<b>29,410</b>
Lifar Distribuidora de Produtos Farmacêuticos Ltda.	Indirect equity interest	<b>11,592</b>	<b>2,932</b>	<b>8,660</b>
Dimesul Gestão Imobiliária Ltda.	Direct equity interest	<b>43,028</b>	<b>288</b>	<b>42,740</b>

  

<b>Subsidiaries - 2021</b>	<b>12/31/2021</b>			
	<b>Control</b>	<b>Assets</b>	<b>Liabilities</b>	<b>Equity</b>
Laboratório Industrial Farmacêutico Lifar Ltda.	Direct equity interest	39,677	11,772	27,905
Lifar Distribuidora de Produtos Farmacêuticos Ltda.	Indirect equity interest	12,550	4,489	8,061
Dimesul Gestão Imobiliária Ltda.	Direct equity interest	41,983	4,094	37,889

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 12. Property, plant and equipment

#### a) Summary of changes in property, plant and equipment (Individual)

The property, plant and equipment balance comprises own and leased assets. Leased properties are included in “Right of use”.

Individual	Properties	Machinery and equipment	Furniture and fixtures	Facilities	Computers and peripherals	Vehicles and aircraft	Improvements	Right of use	Total
Balance at December 31, 2021									
Cost	76,658	60,572	40,388	120,950	63,309	7,860	148,943	782,922	1,301,602
Accumulated depreciation	(8,372)	(16,610)	(18,879)	(51,104)	(43,597)	(2,410)	(34,772)	(261,691)	(437,435)
Net book balance	68,286	43,962	21,509	69,846	19,712	5,450	114,171	521,231	864,167
Acquisitions	376	2,356	2,466	3,942	3,338	21,251	11,256	56,652	101,637
Write-offs	-	(1,343)	(101)	(554)	(60)	-	(941)	(307)	(3,267)
Depreciation	(288)	(981)	(842)	(2,562)	(1,895)	(220)	(2,784)	(32,224)	(41,796)
Balance at March 31, 2022	68,374	43,994	23,032	70,711	21,095	26,481	121,702	545,352	920,741
Cost	77,035	61,105	43,243	119,214	66,515	28,970	162,782	839,574	1,398,438
Accumulated depreciation	(8,661)	(17,111)	(20,211)	(48,503)	(45,420)	(2,489)	(41,080)	(294,222)	(477,697)
Net book balance	68,374	43,994	23,032	70,711	21,095	26,481	121,702	545,352	920,741



## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 12. Property, plant and equipment (Continued)

#### b) Summary of changes in property, plant and equipment (Consolidated)

<b>Consolidated</b>	<b>Properties</b>	<b>Machinery and equipment</b>	<b>Furniture and fixtures</b>	<b>Facilities</b>	<b>Computers and peripherals</b>	<b>Vehicles and aircraft</b>	<b>Improvements</b>	<b>Right of use</b>	<b>Total</b>
Balance at December 31, 2021									
Cost	82,848	67,345	41,006	124,547	63,894	7,938	153,784	782,922	1,324,284
Accumulated depreciation	(11,920)	(19,943)	(19,353)	(53,432)	(44,078)	(2,488)	(37,273)	(261,691)	(450,178)
Net book balance	70,928	47,402	21,653	71,115	19,816	5,450	116,511	521,231	874,106
Acquisitions	376	2,356	2,466	3,996	3,338	21,251	11,301	56,652	101,736
Write-offs	(43)	(1,374)	(101)	(514)	(60)	-	(941)	(307)	(3,340)
Depreciation	(294)	(1,056)	(848)	(2,644)	(1,908)	(220)	(2,833)	(32,224)	(42,027)
Balance at March 31, 2022	70,967	47,328	23,170	71,953	21,186	26,481	124,038	545,352	930,475
Cost	82,086	67,765	43,861	122,866	67,100	29,048	167,668	839,574	1,419,968
Accumulated depreciation	(11,119)	(20,437)	(20,691)	(50,913)	(45,914)	(2,567)	(43,630)	(294,222)	(489,493)
Net book balance	70,967	47,328	23,170	71,953	21,186	26,481	124,038	545,352	930,475

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 12. Property, plant and equipment (Continued)

c) Other information

The Company detected no indication that assets could be recorded at an amount above their recoverable amount.

The weighted average depreciation rates of property, plant and equipment are as follows:

	Average depreciation rate (% p.a.)	
	2022	2021
Properties	1.7	1.7
Machinery and equipment	6	6
Furniture and fixtures	9	9
Facilities	10	10
Computers and peripherals	25	25
Vehicles	20	20
Improvements	7	7

  

Breakdown of rights-of-use		Individual and Consolidated
Description	Useful life (years)	03/31/2022
Properties	2 to 17	544,339
Vehicles	2 to 3	1,013
<b>Total</b>		<b>545,352</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 13. Intangible assets

#### a) Summary of changes in intangible assets (Individual)

Individual	Goodwill	Software	Trademarks and formulas	Total
Balance at December 31, 2021				
Cost	25,341	89,792	361	115,494
Accumulated amortization	(18,072)	(37,867)	(13)	(55,952)
Net book balance	7,269	51,925	348	59,542
Acquisitions	352	6,804	-	7,156
Write-offs	-	(500)	-	(500)
Amortization	(425)	(3,535)	-	(3,960)
Balance at March 31, 2022	7,196	54,694	348	62,238
Cost	25,464	96,092	361	121,917
Accumulated amortization	(18,268)	(41,398)	(13)	(59,679)
Net book balance	7,196	54,694	348	62,238

#### b) Summary of changes in intangible assets (Consolidated)

Consolidated	Goodwill	Software	Trademarks and formulas	Total
Balance at December 31, 2021				
Cost	25,342	90,641	513	116,496
Accumulated amortization	(18,072)	(38,315)	(165)	(56,552)
Net book balance	7,270	52,326	348	59,944
Acquisitions	352	6,837	-	7,189
Write-offs	-	(500)	-	(500)
Amortization	(426)	(3,566)	-	(3,992)
Balance at March 31, 2022	7,196	55,097	348	62,641
Cost	25,464	96,974	513	122,951
Accumulated amortization	(18,268)	(41,877)	(165)	(60,310)
Net book balance	7,196	55,097	348	62,641

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 13. Intangible assets (Continued)

c) Other information

The Company detected no indication that assets could be recorded at an amount above their recoverable amount.

The weighted average amortization rates of intangible assets are as follows:

	Average amortization rate (% p.a.)	
	2022	2021
Goodwill	25	25
Software	18	18
Trademarks e formulas	10	10

### 14. Deferred income and social contribution taxes, net

Deferred income and social contribution taxes are calculated on the corresponding temporary differences between the tax bases of assets and liabilities and their carrying amounts recorded in the interim financial statements. The applicable tax rates, currently defined for calculation of deferred taxes, are 25% for income tax and 9% for social contribution tax.

Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available to offset temporary differences, based on deferred income projections prepared and grounded on internal assumptions and future economic scenarios that may, therefore, suffer changes.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 14. Deferred income and social contribution taxes, net (Continued)

Temporary additions	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Provision for inventory losses	400	476	528	483
Provision for labor indemnities	8,498	9,326	8,840	9,326
Provision for civil contingencies	6,000	6,000	6,000	6,000
Provision for profit sharing	1,612	12,990	1,612	12,990
Provision for tax contingencies	710	908	2,112	908
Reversal of expected credit losses	6,341	5,361	6,342	5,361
Provision for financial discount	1,011	552	1,011	551
Provision for credit card fee	5,179	5,179	5,179	5,179
Provision for premium - employees	449	600	449	600
Net effect of depreciation and interest (IFRS 16) with lease payment	38,434	33,260	38,434	33,260
Fair value - matching shares	3,418	2,670	3,418	2,670
Provision for collective bargaining	-	1,220	15	1,220
Provision for commissions	279	-	279	-
Provision for professional fees	1,575	1,020	2,130	1,026
<b>Total tax base</b>	<b>73,906</b>	<b>79,562</b>	<b>76,349</b>	<b>79,574</b>
Income tax at the rate of 25%	18,477	19,891	19,087	19,893
Income tax on tax loss	11,632	11,723	13,596	13,230
Social contribution tax at the rate of 9%	6,652	7,161	6,871	7,162
Social contribution tax on tax loss	4,920	4,947	5,626	5,505
<b>Total deferred tax assets</b>	<b>41,681</b>	<b>43,722</b>	<b>45,180</b>	<b>45,790</b>
<b>Temporary exclusions</b>				
Exclusion of ICMS from the PIS and COFINS tax base	(15,815)	(19,788)	(18,623)	(22,604)
Adjustments due to leases	(3,478)	(3,701)	(3,478)	(3,701)
<b>Total tax base</b>	<b>(19,293)</b>	<b>(23,489)</b>	<b>(22,101)</b>	<b>(26,305)</b>
Income tax at the rate of 25%	(4,823)	(5,872)	(5,525)	(6,576)
Social contribution tax at the rate of 9%	(1,736)	(2,114)	(1,989)	(2,368)
<b>Total deferred tax liabilities</b>	<b>(6,559)</b>	<b>(7,986)</b>	<b>(7,514)</b>	<b>(8,944)</b>
<b>Total deferred taxes, net</b>	<b>35,122</b>	<b>35,736</b>	<b>37,666</b>	<b>36,846</b>

The Company and its subsidiary LIFAR will subject to the IRPJ and CSLL taxation the PIS and COFINS credits arising from the lawsuits to exclude the ICMS from the PIS and COFINS tax base, on which a res judicata decision has been awarded, to the extent that they are the subject of requests for offsetting. Accordingly, a deferred liability was recognized on the amounts that will be realized as the referred to offsets occur, in the amounts of R\$15,815 in the Individual and R\$18,624 in the Consolidated interim financial statements as at March 31, 2022 (R\$19,788 and R\$22,604 in the Individual and Consolidated financial statements, respectively, as at December 31, 2021).

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### 14. Deferred income and social contribution taxes, net (Continued)

Based on the Company's deferred income projections and considering the history of realization of the assets that generated the income and social contribution tax balance, the estimated realization schedule is as follows:

	03/31/2022	
	Individual	Consolidated
2022	20,841	22,592
2023	5,210	5,647
2024	5,210	5,647
2025	5,210	5,647
2026	5,210	5,647
	<b>41,681</b>	<b>45,180</b>

### 15. Reconciliation of income and social contribution taxes

	Individual		Consolidated	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021
<b>Income before income and social contribution taxes</b>	<b>15,254</b>	26,878	<b>14,670</b>	26,346
Combined tax rate	34%	34%	34%	34%
Tax expense at nominal rate	<b>(5,186)</b>	(9,139)	<b>(4,988)</b>	(8,958)
Equity pickup	<b>2,091</b>	(89)	-	-
IRPJ/CSLL - Tax credits (*)	<b>12,811</b>	-	<b>12,811</b>	-
Tax incentives - Worker's Meal Program (PAT)	-	69	2	69
Tax incentives - investment grant - matching credit	<b>1,385</b>	1,178	<b>1,385</b>	1,178
Tax incentives - investment grant - Other credits	<b>973</b>	-	<b>973</b>	-
Reversal of the effect of the taxable profit based on accounting records regime on the subsidiary using the taxable profit based on a percentage of gross revenue regime	-	-	<b>1,797</b>	258
Taxation under the taxable profit based on a percentage of gross revenue regime using gross revenue for the tax base	-	-	<b>(435)</b>	(75)
Tax incentives – Technological innovation – Benefit	<b>349</b>	1,178	<b>703</b>	1,178
Other nondeductible expenses	<b>(7,069)</b>	206	<b>(6,310)</b>	285
	<b>5,354</b>	<b>(6,597)</b>	<b>5,938</b>	<b>(6,065)</b>
Income and social contribution taxes in profit or loss for the period				
Current income and social contribution taxes	<b>5,967</b>	(3,822)	<b>5,118</b>	(4,203)
Deferred income and social contribution taxes	<b>(613)</b>	(2,775)	<b>820</b>	(1,862)
Income and social contribution taxes in profit or loss for the period	<b>5,354</b>	<b>(6,597)</b>	<b>5,938</b>	<b>(6,065)</b>
Effective rate	<b>-35.1%</b>	24.5%	<b>-40.5%</b>	23.0%

(\*) IRPJ and CSLL on the amounts reimbursed referring to insurance compensation, resulting from a lawsuit on which a res judicata decision has been awarded, as mentioned in Note 9.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 16. Trade accounts payable

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Trade accounts payable - local	501,010	464,014	503,177	464,714
Trade accounts payable - related parties	4,611	6,103	-	-
<b>Total</b>	<b>505,621</b>	<b>470,117</b>	<b>503,177</b>	<b>464,714</b>

### 17. Loans and financing

	Rate range (% p.a.)	Individual		Consolidated	
		03/31/2022	12/31/2021	03/31/2022	12/31/2021
<b>Domestic currency</b>					
	109% of the				
Debenture - Banco Bradesco	CDI	137,357	133,818	137,357	133,818
		<b>137,357</b>	<b>133,818</b>	<b>137,357</b>	<b>133,818</b>
<b>Current</b>		<b>58,071</b>	54,532	<b>58,071</b>	54,532
<b>Noncurrent</b>		<b>79,286</b>	79,286	<b>79,286</b>	79,286

Management monitors the forecasts for the Company's liquidity requirements to ensure it has sufficient cash to meet its operating needs. The global limits of credit facilities granted to the Company are in amounts sufficient to not generate the risk of exceeding such limits or of breaching loan agreement clauses. This forecast takes into consideration the Company's debt financing plans. The Company has debentures with contractual clauses that require maintaining financial ratios on a quarterly basis as summarized below:

#### 17.1. Debt Service Coverage Ratio ("DSCR") higher than or equal to 1.2 (one and two tenths)

**Where:** "DSCR" means the division of Adjusted EBITDA (as defined below) by the Debt Service; and "Debt Service" means finance costs for the last twelve (12) months calculated under the accrual basis of accounting, on a consolidated basis, by the Issuer, i.e. (a) interest on bank debts (net of income from short-term investments), (b) portion that has an impact on cash from monetary and foreign exchange difference on interest of debt arrangements, (c) interest paid to Debentures and other marketable securities issued in the financial and capital markets, both international and domestic (net of income from investments in marketable securities or in government securities and corporate bonds of any nature), (d) finance costs with cash impact on intercompany loans recorded in liabilities (net of finance income with cash impact received from intercompany loans recorded in assets), as well as (e) the amount effectively disbursed relating to liabilities from derivative transactions hedging debts (net of amounts effectively received in connection with assets from derivative transactions hedging debts).

## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### **17. Loans and financing (Continued)**

#### **17.2. Adjusted Net Financial Debt/Adjusted EBITDA ratio, according to the calculation method described below, not exceeding 2.5 (two and five tenths)**

**Where:** for the calculation of Adjusted EBITDA, the accumulated performance for the last 12 months from the statements closing date, to be measured based on the consolidated statements of financial position for March, June, September and December of each year, shall be considered. For the purposes of this item, the following shall apply: "Adjusted Net Financial Debt" is the sum of amounts corresponding to (i) short-term bank loans; (ii) short-term debentures; (iii) long-term bank loans; (iv) long-term debentures; (v) long-term loans; (vi) short-term bank leases; (vii) long-term bank leases; (viii) accounts payable or receivable in connection with derivative transactions, in the event of less cash equivalents, cash/short-term investments and securities; and also (ix) all intercompany loans recorded in assets and liabilities, between group companies, either associates or not; "Adjusted EBITDA", as provided for in CVM Ruling No. 527 of October 4, 2012, as amended; and "Net Financial Debt/Adjusted EBITDA" is Adjusted Net Financial Debt divided by Adjusted EBITDA.

The Company is compliant with all such clauses at March 31, 2022.

The loan agreements in force also have non-financial early maturity clauses, the most relevant of which are described below:

- Default on debts and/or other contracts with the financial institutions that granted credit facilities;
- Enforcement of a court order or out-of-court order that may affect Dimed's ability to pay;
- Transfer of debt to third parties, without the approval of the financial institution that granted the credit facility;
- Changes in Dimed's business purpose or changes in corporate control without the financial institution's formal acceptance and agreement to maintain contracts.

The Company is compliant with all such clauses at March 31, 2022.



## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 17. Loans and financing (Continued)

#### 17.2. Adjusted Net Financial Debt/Adjusted EBITDA ratio, according to the calculation method described below, not exceeding 2.5 (two and five tenths) (Continued)

The table below shows additional information on cash flow from financing activities:

	Individual and Consolidated			Total
	Finance lease	Loans, financing and debentures	Interest on equity payable	
<b>Balance at December 31, 2021</b>	557,109	133,818	5,701	696,628
<b>Changes in cash</b>	<b>(34,713)</b>	-	<b>(5,809)</b>	<b>(40,522)</b>
Payment of IOE	-	-	(5,809)	(5,809)
Leases paid	(34,713)	-	-	(34,713)
<b>Non-cash changes</b>	<b>63,627</b>	<b>3,539</b>	-	<b>67,166</b>
Remeasurement of contracts and new contracts - IFRS 16	56,345	-	-	56,345
Discount on leased properties	(2,020)	-	-	(2,020)
Interest recognized in the period	9,302	3,539	-	12,841
<b>Balance at March 31, 2022</b>	<b>586,023</b>	<b>137,357</b>	<b>(108)</b>	<b>723,272</b>

The balances of loans and financing at March 31, 2022 and December 31, 2021 are presented at amortized cost. The aging list of loans and financing is presented in Note 4.1 (c) Liquidity risk.

### 18. Tax obligations

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Corporate Income Tax (IRPJ)	1	-	327	437
Social Contribution Tax on Net Profit (CSLL)	1	-	207	234
Contribution Tax on Gross Revenue for Social Integration Program (PIS)	335	114	350	174
Contribution Tax on Gross Revenue for Social Security Financing (COFINS)	1,606	548	1,679	826
Withholding Income Tax (IRRF)	2,193	5,224	2,251	5,291
State Value-Added Tax (ICMS)	13,492	20,247	14,923	22,018
Other obligations	1,548	1,372	1,732	1,821
<b>Total</b>	<b>19,176</b>	<b>27,505</b>	<b>21,469</b>	<b>30,801</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 19. Profit sharing payable

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Bonus - Executive Board	2,827	3,441	2,827	3,441
Employees' profit sharing	1,612	8,717	1,612	8,770
<b>Total</b>	<b>4,439</b>	<b>12,158</b>	<b>4,439</b>	<b>12,211</b>

### 20. Lease obligations

The Company has obligations arising from lease agreements relating to equipment (telephone exchange and Storage) and aircraft, and this asset shall be acquired at the end of the agreement at its residual value. Lease liabilities are guaranteed by assignment in trust of the leased asset.

	Individual and Consolidated		
	Less than 1 year	From 1 to 5 years	Total
<b>At March 31, 2022</b>			
Leases	1,452	785	2,237
<b>At December 31, 2021</b>			
Leases	1,454	1,164	2,618

Changes in the Company's lease liability balance at March 31, 2022 were as follows:

	Individual and Consolidated		
	Properties	Vehicles	Total
<b>Balance at December 31, 2021</b>	553,198	1,293	554,491
Remeasurement of contracts, new contracts and write-offs	56,252	93	56,345
Interest	9,255	47	9,302
Discounts obtained	(2,020)	-	(2,020)
Payment of lease	(34,037)	(295)	(34,332)
<b>Balance at March 31, 2022</b>	<b>582,648</b>	<b>1,138</b>	<b>583,786</b>
<b>Current</b>	<b>140,626</b>	<b>348</b>	<b>140,974</b>
<b>Noncurrent</b>	<b>442,022</b>	<b>790</b>	<b>442,812</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 20. Lease obligations (Continued)

The nominal discount rate adopted by the Company was between 5% and 9.97% for store and vehicle lease agreements. The Company applied the simplified retrospective approach and, at the time of transition, lease liabilities are measured at the present value of the remaining payments, discounted at the incremental borrowing rate. Initially, the Company measured the right to use the assets at an amount equivalent to the lease liability, and used the practical expedient that allows lessees to exclude initial direct costs from the measurement of the right-of-use asset on the date of initial application.

In compliance with CVM Memorandum Circular No. 02/2019 and CPC 06 (R2)/IFRS 16, explained by the fact that the Company did not apply the nominal flow methodology due to the IFRS 16 prohibition of future inflation projection, companies shall present minimum inputs for users of interim financial statements to reach this information. Accordingly, the Company decided to disclose the minimum inputs below for users to reach that information. Inputs are:

- Nominal average discount rate applied - between 5% and 9.97% p.a.; and
- Inflation component to be used in projecting the flows (Extended Consumer Price Index - IPCA, based on National Treasury Notes - NTN-B) - 3.6% p.a.

### 21. Provisions

The Company is a party to civil, labor and tax claims, in administrative and legal proceedings. Where applicable, claims are supported by judicial deposits. Provisions for any losses arising from these proceedings are estimated and restated by management, supported by the opinion of its external and internal legal advisors.

The proceedings considered as possible or probable losses, in the opinion of the Company's legal advisors, at March 31, 2022 and December 31, 2021, are presented below. Provisions are recognized for proceedings assessed as probable losses, as follows:

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Civil	6,000	6,000	6,000	6,000
Labor and tax	9,208	10,234	10,952	12,101
<b>Noncurrent</b>	<b>15,208</b>	<b>16,234</b>	<b>16,952</b>	<b>18,101</b>
<b>Judicial deposits</b>	<b>3,487</b>	<b>3,411</b>	<b>3,952</b>	<b>3,875</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 21. Provisions (Continued)

Changes in provisions for civil, labor and tax claims are shown in the table below:

	Individual		Consolidated	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
<b>Civil, labor and tax</b>				
Balance at beginning of year	16,234	14,074	18,101	14,419
New provisions	-	12,514	65	15,865
Write-off due to payment	(1,026)	(3,666)	(1,026)	(3,666)
Reversal	-	(6,688)	(188)	(8,517)
Closing balance	15,208	16,234	16,952	18,101

#### a) Civil

At March 31, 2022, the Company was party to 93 civil lawsuits assessed as possible losses, with an estimated value of approximately R\$51,915 in the individual and consolidated interim financial statements (approximately R\$46 million in the individual and consolidated financial statements at December 31, 2021). Of this amount, the most significant lawsuit subject matter is Law No. 10209/2001 (Toll Allowance Law). Such lawsuit is under discussion at the Federal Supreme Court of Brazil (STF), and is currently undergoing legal investigation at the source, with an estimated total amount of approximately R\$55,919, and estimated possible loss of R\$47,329 (approximately R\$51,616 and estimated possible loss of R\$43,735 at December 31, 2021).

#### b) Labor

The most recurring labor claims involve overtime and salary differences. At March 31, 2022, the Company had 621 possible-loss labor lawsuits in the consolidated interim financial statements, estimated at R\$49,808, of which 601 lawsuits in the amount of R\$49,265 correspond to parent company's lawsuits (R\$20,272 in the Individual and R\$20,823 in the Consolidated financial statements at December 31, 2021). Of this amount, the most significant claim refers to the issue of CAT (Occupational Accident Report) for all employees who were infected by COVID-19, regardless of the causal link. Such lawsuit is in its initial phase, with an estimated total amount of approximately R\$24,000, and estimated possible loss of R\$24,000.

#### c) Tax

At March 31, 2022, the Company was party to approximately 291 tax lawsuits assessed as possible losses, at an estimated amount of R\$36 million (R\$36 at December 31, 2021) in the individual and consolidated interim financial statements.

## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### **22. Investments grants and matching credits**

In December 2011, the Company received public land in the urban area of the municipality of Eldorado do Sul, in Rio Grande do Sul state, as donation. This land has 50,000 square meters and is intended for the construction of a new Distribution Center. Based on the guidance of CPC 07, the grant received was classified as a non-monetary asset, based on the fair value recorded in books, and was initially recognized at R\$5,026 in property, plant and equipment at December 31, 2011. Based on this criterion, this grant was recognized with a temporary matching entry in liabilities, considering that the economic benefits are deferred to the time of its use and are contingent on the Company complying with the obligations provided for by Municipal Law No. 3067 of December 13, 2011. The main commitments made with the municipality are the following: return of ICMS, to be calculated as from the beginning of activities, hiring of 270 direct employees and 25 indirect employees, and the transfer of licensing of its fleet. At the end of the five-year period, if the Company fails to return the amounts, the total amount of the incentives granted shall be paid to the local government, restated by reference to the Extended Consumer Price Index (IPCA) disclosed by the Brazilian Institute of Geography and Statistics (IBGE).

In the second quarter of 2014, ten thousand square meters were added to the public land donated in this municipality, recorded in that period at fair value, i.e. R\$1,000, under property, plant and equipment. This supplementary grant was recorded based on the same accounting criteria adopted for the initial recognition of the original grant. At December 31, 2018, the Company recognized the remaining amount of the grant, i.e. R\$1,226.

In 2017, Supplementary Law No. 160/17 was approved and it is intended to promote important changes regarding tax benefits granted unilaterally by the Brazilian states. New rules were established for the classification of these tax benefits as "investment grants", thus exempting them from PIS, COFINS, IRPJ and CSLL. In the first quarter of 2022, the amount of R\$4,075 (R\$11,310 at December 31, 2021), referring to matching credit grant, was recognized in the statement of profit or loss.

### **23. Equity**

#### a) Capital

At the Special General Meeting held on March 20, 2020, the shareholders approved the proposal of splitting all existing shares issued by the Company, both common and preferred shares, with each one (1) existing share corresponding to thirty (30) shares. Consequently, the Company's capital is now represented by 121,994,700 common shares and 13,485,690 preferred shares.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 23. Equity (Continued)

#### a) Capital (Continued)

At the Special General Meeting held on July 17, 2020, capital increase from R\$410,000 to R\$432,000 was approved, through capitalization of part of the Legal Reserve, in the amount of R\$4,832, and part of Reserve for capital increase, in the amount of R\$17,168, without issue of new shares.

On July 22, 2020, as a result of the Follow-on operation carried out by the Company, capital was increased by R\$480,000. Accordingly, at December 31, 2020, the Company's capital amounted to R\$912,000 (R\$897,552 net of share issue costs) fully paid in (R\$410,000 at December 31, 2019), represented by 137,994,700 common shares and 13,485,690 preferred shares, all of the same class and with no par value.

At the Annual and Special General Meeting held on April 30, 2021, the shareholders approved, respectively, the managing officers' accounts, the management report, the financial statements and the independent auditor's report for the year ended December 31, 2020, and the capital increase, from R\$912,000 to R\$918,000, through the capitalization of a portion of the Legal Reserve, in the amount of R\$1,006 and of the Reserve for capital increase, in the amount of R\$4,994, without issue of new shares.

At the General and Special Preferred Shareholders' Meeting held on May 24, 2021, conversion of all the Company's preferred shares was approved.

The period during which the Company's preferred shareholders could request the conversion of preferred shares held by them into common shares, in the proportion of 0.8 (eight tenths) of a common share for each 1 (one) converted preferred share, ended June 14, 2021 ("Voluntary Conversion"). Under the Voluntary Conversion, on June 23, 2021, the shareholders of 5,514,545 preferred, registered, book-entry shares with no par value, equivalent to 40.8918% of total preferred shares issued by the Company at the time, requested the conversion of their shares into 4,411,636 common, registered, book-entry shares with no par value issued by the Company. This operation was conducted on July 7, 2021, and the Company's capital then comprised 142,406,336 common shares and 7,971,145 preferred shares. Each common share entitles the holder thereof to one vote at the General Meetings.

On July 26, 2021, the period for preferred shareholders to exercise the right to withdraw from the resolution at the special general preferred shareholders' meeting, held on May 24, 2021, ended. At the end of the period of withdrawal rights, on August 4, 2021, the Company converted ("Compulsory Conversion") all of its preferred shares, and its capital then comprised 150,377,481 common shares only. Each common share entitles the holder thereof to one vote at the General Meetings.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 23. Equity (Continued)

#### b) Treasury shares

At the Board of Directors' Meeting held on August 13, 2020, the creation of a Share Buyback Program issued by the Company was approved, without reducing capital. At the Board of Directors' Meeting held on August 16, 2021, the Company approved the renewal of its Share Buyback Plan. The program is valid from August 17, 2021 to August 16, 2022, with a maximum repurchase limit of 2,000,000 (two million) common shares. The information was disclosed to the Market on August 17, 2021, through a Material News Release. The purposes of the Share Buyback Program are to maximize the generation of value for shareholders, based on an adequate capital structure combined with the growth of results and earnings from shares, as well as enabling the implementation of long-term incentive plans, through which executive officers will receive shares issued by the Company (see Note 24 - Incentive plan in connection with shares).

At March 31, the Company had 1,799,157 treasury shares (1,849,157 at December 31, 2021) whose average cost value was R\$37,272 (R\$36,690 at December 31, 2021). The share market price at March 31, 2022 is R\$14.27 (R\$13.32 at December 31, 2021).

Changes in treasury shares are as follows:

	<u>Individual</u>		
	<u>Common Shares</u>	<u>R\$</u>	
Balance at 12/31/2021	(1,849,157)	(36,690)	
Acquisition of shares	<b>(50,000)</b>	<b>(582)</b>	
<b>Balance at 03/31/2022</b>	<b>(1,899,157)</b>	<b>(37,272)</b>	

  

	<u>Share price</u>		
	<u>Minimum</u>	<u>Maximum</u>	<u>Average cost</u>
From 01/01/2021 to 12/31/2021	11.98	22.94	17.79
<b>From 01/01/2022 to 03/31/2022</b>	<b>10.79</b>	<b>14.38</b>	<b>12.59</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 23. Equity (Continued)

c) Income reserves

i) *Reserve for future capital increase*

The purpose of this reserve is to increase Dimed's investments in working capital for expansion projects, as provided for in article 24, clause "c", of Dimed's Articles of Incorporation. The use of the balance of this reserve was approved by the shareholders at the Annual General Meeting held on July 17, 2020. In 2021, the balance of this reserve was fully used to pay in the capital, as mentioned in item b) above. In December 2021, the amount of R\$24,274 was recorded as a reserve for future capital increase, and this balance was maintained in the first quarter of 2022.

ii) *Legal reserve*

The legal reserve is set up at 5% of net income for each year, under the terms of Law No. 6404/76, article 193, capped at 20% of the capital.

iii) *Dividends and interest on equity additional to those proposed*

This reserve is recognized in relation to dividends exceeding the mandatory minimum dividends of 25%, as provided for by law and approved by the shareholders.

iv) *Compensation paid to shareholders*

In accordance with the provisions of Dimed's Articles of Incorporation, the mandatory minimum dividend is 25% on net income for the year, considering the adjustments provided for in the corporation law.

On August 6, 2021, the Company resolved on the payment of interest on equity to its shareholders in the amount of R\$6,000, effectively paying, until December 31, 2021, the amount of R\$5,946 (net of income tax equivalent to R\$5,275), which was credited on August 31, 2021, based on the shareholding position of August 20, 2021.

On December 17, 2021, the Company decided to distribute R\$20,000 to be paid in 3 (three) installments, respectively on 03/31/2022, 04/29/2022 and 05/31/2022. The total amount distributed by the Company, approved on December 17, 2021, also comprises the remaining amount of R\$55, referring to the distribution approved on August 6, 2021.

From the resolution on August 6, 2021, the unit value per share, net of IRRF, was R\$0.03 per common share. On December 17, 2021, the unit value per share, net of IRRF, was R\$0.114453201.



## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 23. Equity (Continued)

#### d) Capital reserves

This is set up and matched against the expenses with the stock option plan granted by the Company to its managing officers and employees (Note 24).

### 24. Incentive plan in connection with shares - Individual

#### Matching Shares

At the Special General Meeting held on September 8, 2020, the shareholders approved the creation of the Incentive Plan in connection with the Company's shares ("Dimed's Matching Shares Plan" or "Plan").

The purpose of the Company's Share-Based Incentive Plan is to rule the possibility of granting incentives in connection with the Company's common shares to managing officers and employees with whom it has employment or statutory relationship, aimed at: (i) increasing the capacity to attract talent; (ii) reinforcing the culture of sustainable performance and the search for the development of managing officers and employees, aligning their personal and professional interests with those of the shareholders; and (iii) enabling the Company to retain its professionals, offering them, as an additional advantage and incentive, the opportunity to become shareholders. The shares granted as an incentive under the Dimed's Matching Shares Plan may not exceed the maximum limit of 3% of the shares of the Company's subscribed and paid-in capital.

Beneficiaries will be granted the right to receive, free of charge, the maximum proportion of up to four (4) and minimum of one (1) Matching Share for each common share of the Company, acquired under the Plan ("Own Shares"), up to the limit established in their respective Private Share Granting Instruments and Adhesion to Dimed's Matching Shares Plan, provided that certain conditions are met.

Matching Shares will be subject to a progressive Vesting Period of four years, during which the beneficiary must maintain his/her relationship with the Company. The Vesting Period will start on the grant date and within this period the Matching Shares will become Mature Matching Shares and will be liquidated to the beneficiaries on the dates specified below:

<u>Anniversary</u>	<u>Mature Matching Shares</u>
1st anniversary of the Grant Date	-
2 <sup>nd</sup> anniversary of the Grant Date	1/3 (one third) of the total Matching Shares
3 <sup>rd</sup> anniversary of the Grant Date	1/3 (one third) of the total Matching Shares
4 <sup>th</sup> anniversary of the Grant Date	1/3 (one third) of the total Matching Shares

## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### **24. Incentive plan in connection with shares - Individual (Continued)**

#### Matching Shares (Continued)

Upon execution of the grant agreement, the beneficiary must expressly authorize the blocking of the negotiation and encumbrance of the "Own Shares" acquired, during the Vesting period, in the records of the depositary institution of the Company's book-entry shares.

In September 2020, 69,802 "Own Shares" and 200,376 "Matching Shares" were granted to the Plan's participants, and until March 31, 2021, 66,382 "Own Shares" had been subscribed. There were no new changes through March 31, 2022.

At the Board of Directors' meeting held on April 20, 2021, the creation of Dimed's second Matching Shares program was approved, under the same conditions as the first program. On July 9, 2021, share transfer orders were formalized, with the adherence of 27,545 "Own Shares"; 22,000 Book-entry Shares; 4,423 shares not yet transferred and R\$169,094 "Matching Shares".

In the first quarter of 2022, the Company recognized R\$748 as expense with the Matching Shares program, matched against the groups of selling (R\$664) and administrative (R\$84) expenses.

### **25. Earnings per share**

#### a) Basic

Basic earnings per share are calculated by dividing the profit attributable to the Company's shareholders by the weighted average number of common shares issued during the year, excluding common shares purchased by the Company and held as treasury shares.

#### b) Diluted

Diluted earnings per share are calculated by adjusting the weighted average number of outstanding common shares, to assume the conversion of all dilutive potential common shares.

As required by IAS 33/CPC 41, the number of shares used to calculate earnings (loss) per share for the current period and the comparative period were affected by the referred to share split.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 25. Earnings per share (Continued)

#### b) Diluted (Continued)

	03/31/2022		
	Common registered shares	Total	
<b>Denominator</b>			
Total weighted average number of shares	150,377,481	150,377,481	
Weighted number of treasury shares	(1,897,247)	(1,897,247)	
Weighted average number of outstanding shares	148,480,234	148,480,234	
% of shares in relation to the total number	100%	100%	
<b>Numerator</b>			
Net income attributable to each class of share	20,607,800	20,607,800	
Weighted average number of outstanding shares	148,480,234		
<b>Basic earnings per share (R\$)</b>	<u>0.14</u>		
<b>Numerator</b>			
Net income attributable to each class of share	20,607,800	20,607,800	
Weighted average number of outstanding shares	148,480,234		
Weighted average number of matching shares	369,470		
<b>Diluted earnings per share (R\$)</b>	<u>0.14</u>		
	03/31/2021		
	Registered common shares	Registered preferred shares	Total
Denominator			
Total weighted average number of shares	137,994,700	13,485,690	151,480,390
Weighted number of treasury shares	(1,158,473)	-	(1,158,473)
Weighted average number of outstanding shares	136,836,227	13,485,690	150,321,917
% of shares in relation to the total number	91.03%	8.97%	100.00%
<b>Numerator</b>			
Net income attributable to each class of shares (R\$)	18,296,560	1,983,509	20,280,069
Weighted average number of outstanding shares	136,836,227	13,485,690	
<b>Basic earnings per share (R\$)</b>	<u>0.13</u>	<u>0.15</u>	

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 25. Earnings per share (Continued)

#### Migration to the Novo Mercado (B3)

Throughout 2021, the Company made progress in its commitment to shareholders, to raise its Corporate Governance standard to the highest level at B3 (Brasil, Bolsa, Balcão). The migration process to the Novo Mercado was completed and shares began to be traded at this level on September 24, 2021. The process was started at the beginning of the year, upon approval of the conversion of preferred shares into common shares, effective on August 3, 2021, date on which the Company became holder of common shares only. The Company, throughout the referred process, also complied with the necessary requirements, such as the creation of internal committees, amendment to the Company's by-laws and the election of independent members in the Board of Directors.

### 26. Revenues

The Company's revenue derives mainly from the resale of drugs and personal care and beauty products.

Reconciliation between gross revenues for tax purposes and the revenues stated in the statement of profit or loss for the period is as follows:

	Individual		Consolidated	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021
Gross sales of products and services	<b>962,656</b>	808,660	<b>969,334</b>	811,830
Sales taxes	<b>(55,127)</b>	(47,713)	<b>(55,971)</b>	(49,177)
Returns and unconditional discounts	<b>(11,647)</b>	(9,953)	<b>(11,813)</b>	(10,315)
Net revenue	<b>895,882</b>	750,994	<b>901,550</b>	752,338

### 27. Cost of goods sold and services rendered

	Individual		Consolidated	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021
Cost of goods sold	<b>(674,333)</b>	(559,104)	<b>(668,597)</b>	(552,731)
Cost of sales	-	-	<b>(5,868)</b>	(5,869)
Reimbursement of capital contribution costs	<b>53,045</b>	42,913	<b>53,045</b>	42,913
Revenue - campaign funds	<b>276</b>	432	<b>276</b>	432
Taxes on funds	<b>(4,932)</b>	(4,009)	<b>(4,932)</b>	(4,009)
	<b>(625,944)</b>	(519,768)	<b>(626,076)</b>	(519,264)



## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 29. Other operating income (expenses)

	Individual		Consolidated	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021
Additional revenue	567	230	592	255
Revenue from property lease	26	66	26	66
Credit recovery	4,963	867	4,963	867
Reimbursement of cash difference	76	62	76	62
Cost of disposal of PPE	(450)	(384)	(450)	(384)
Other operating income (expenses)	475	(26)	496	(26)
Recovery of tax credits (*)	-	10,777	-	10,777
	<b>5,657</b>	<b>11,592</b>	<b>5,703</b>	<b>11,617</b>

(\*) This refers to credits related to the proceeding that excludes the ICMS from the PIS/COFINS tax base recognized in the quarter. Additional information is disclosed in Note 10.

### 30. Finance income and costs

	Individual		Consolidated	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021
<b>Finance income</b>				
Interest on assets	155	115	156	144
Monetary variations	-	-	-	24
Short-term investment yield	2,689	1,598	3,880	1,821
Financial discounts obtained	294	286	295	288
Taxes on finance income	(348)	(440)	(360)	(441)
Monetary restatement of tax credits (*)	299	7,464	390	7,464
	<b>3,089</b>	<b>9,023</b>	<b>4,361</b>	<b>9,300</b>

(\*) This refers to the monetary restatement of credits related to the proceeding that excludes the ICMS from the PIS/COFINS tax base recognized in the quarter. Additional information is disclosed in Note 10.

	Individual		Consolidated	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021
<b>Finance costs</b>				
Interest on financing	(3,540)	(977)	(3,540)	(977)
Interest expenses	(100)	(49)	(103)	(50)
Financing charges	(77)	(50)	(77)	(50)
Discounts granted/bonus	(1,826)	(1,198)	(1,864)	(1,253)
Interest on lease	(9,302)	(5,302)	(9,302)	(5,302)
Other finance costs	(605)	(387)	(647)	(431)
	<b>(15,450)</b>	<b>(7,963)</b>	<b>(15,533)</b>	<b>(8,063)</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 31. Transactions with related parties

#### a) Balances and transactions

The total amounts of transactions carried out by Dimed, through March 31, 2022, with related parties are described below:

	Dimesul Gestão Imobiliária Ltda.		Laboratório Industrial e Farmacêutico Lifar Ltda.	
	03/31/2022	12/31/2021	03/31/2022	12/31/2021
Trade accounts payable	-	-	4,611	6,103
Related parties - intercompany loans	-	-	-	(1,670)
	Dimesul Gestão Imobiliária Ltda.		Laboratório Industrial e Farmacêutico Lifar Ltda.	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021
Purchase of goods and services	-	-	9,916	44,156
Revenue from services rendered	398	2,616	38	153
			Accounts receivable from shareholders	
			03/31/2022	12/31/2021
Share issue costs (secondary offering)			2,530	3,030

Sales transactions between related parties are conducted at amounts agreed by and between the companies, with days sales/payable outstanding of 30 days. The balance of the intercompany loan agreement is restated monthly at the benchmark rate of the Central Bank of Brazil (SELIC).

#### b) Key management personnel compensation

The table below contains information on key management personnel compensation (individual):

	Individual	
	03/31/2022	03/31/2021
Fixed compensation	1,433	1,205
Social charges	401	337
Profit sharing	648	-
<b>Total</b>	<b>2,482</b>	<b>1,542</b>

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### 31. Transactions with related parties (Continued)

#### b) Key management personnel compensation (Continued)

These amounts are stated under “General and administrative expenses” in the statement of profit or loss and are detailed in Note 28. Management is also part of the Incentive Plan in connection with the Company’s shares, created to regulate the possibility of granting incentives through common shares issued by the Company.

Managing officers were granted the right to receive, free of charge, the proportion of three (3) and four (4) Matching Share for each common share of the Company, acquired under the Plan (“Own Shares”), for which a fair value of R\$2,308 was recorded in 2021, up to the limit established in their respective Private Share Granting Instruments and Adhesion to Dimed's *Matching Shares* Plan, provided that certain conditions are met. In the first quarter of 2022, the Company recognized an amount of R\$648 as fair value, which corresponds to the Matching shares of managing officers. Additional information can be found in Note 24.

### 32. Insurance coverage

The Company has insurance policies that consider the nature and degree of risks involved. At March 31, 2022, the Company and its subsidiaries had insurance coverage for vehicles, fire, civil liability, cargo transportation and aircraft, among others. The insurance coverage sufficiency is under the responsibility of Company management that considers it adequate to cover losses, if any. The Maximum Indemnification Limits for the main insurance policies are as follows:

<u>Policies</u>	<u>Amounts in R\$ thousands</u>
Vehicle	FIPE Table + Property Damage + Bodily Injury
Fire	R\$ 529,445
Civil liability	R\$ 31,200
Transportation	R\$1,300 per transportation
Aircraft	R\$20,483 (*)
Civil liability – aircraft	R\$94,750 (*)

(\*) Policy issued in US Dollar, amount translated at the average rate (dollar) of March 31, 2022 (R\$4.7375).



## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)  
March 31, 2022  
(In thousands of reais)

### **33. Segment reporting**

Segment reporting is presented based on the management reports used by the Board of Directors, the board responsible for the Company's strategic decision-making, to manage the business. The Company's segments are divided into Retail, Wholesale and Corporate, which include all administrative expenses, as well as finance income (costs).

The Retail segment has 527 stores that sell more than 15 thousand items among drugs and personal care and beauty products, The Wholesale segment is one of the main distributors of drugs in Brazil and also the pioneer in the country in its segment. Lastly, the Corporate segment includes Wholesale and Retail, as well as subsidiary Lifar (Laboratório Farmacêutico Lifar Ltda.). In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of major brands in Brazil, as well as products of its own brand Panvel. Subsidiary Dimesul is engaged in the purchase, sale, intermediation, subdivision, lease, rent, management and administration of own or third-party properties, with a view to centralizing and optimizing the management of the Company's properties.

## Dimed S.A. Distribuidora de Medicamentos

Notes to quarterly information (Continued)  
 March 31, 2022  
 (In thousands of reais)

### 33. Segment reporting (Continued)

	Retail		Wholesale		Corporate		Dimed S.A.	
	03/31/2022	03/31/2021	03/31/2022	03/31/2021	03/31/2022	03/31/2021	03/31/2022	03/31/2021
Continuing operations								
Net revenue from sales and services	<b>806,153</b>	689,098	<b>95,397</b>	63,240	-	-	<b>901,550</b>	752,338
Cost of goods sold and services rendered	<b>(564,861)</b>	(466,386)	<b>(61,215)</b>	(52,878)	-	-	<b>(626,076)</b>	(519,264)
Gross profit	<b>241,292</b>	222,712	<b>34,182</b>	10,362	-	-	<b>275,474</b>	233,074
Selling expenses	-	-	-	-	<b>(231,461)</b>	(196,312)	<b>(231,461)</b>	(196,312)
Other operating income (expenses), net	-	-	-	-	<b>5,703</b>	11,617	<b>5,703</b>	11,617
Administrative expenses	-	-	-	-	<b>(23,874)</b>	(23,270)	<b>(23,874)</b>	(23,270)
Operating income before finance income (costs)	<b>241,292</b>	222,712	<b>34,182</b>	10,362	<b>(249,632)</b>	(207,965)	<b>25,842</b>	25,109
<u>Finance income (costs)</u>	-	-	-	-	<b>(11,172)</b>	1,237	<b>(11,172)</b>	1,237
Finance income	-	-	-	-	<b>4,361</b>	9,300	<b>4,361</b>	9,300
Finance costs	-	-	-	-	<b>(15,533)</b>	(8,063)	<b>(15,533)</b>	(8,063)
Operating income before income and social contribution taxes	<b>241,292</b>	222,712	<b>34,182</b>	10,362	<b>(260,804)</b>	(206,728)	<b>14,670</b>	26,346
Current	-	-	-	-	<b>5,118</b>	(4,203)	<b>5,118</b>	(4,203)
Deferred	-	-	-	-	<b>820</b>	(1,862)	<b>820</b>	(1,862)
Net income for the year	<b>241,292</b>	222,712	<b>34,182</b>	10,362	<b>(254,866)</b>	(212,793)	<b>20,608</b>	20,281

## **Dimed S.A. Distribuidora de Medicamentos**

Notes to quarterly information (Continued)

March 31, 2022

(In thousands of reais)

### **34. Events after the reporting period**

On April 25, 2022, through the Minutes of the Board of Directors' Meeting, the members approved the issue of the Company's 4<sup>th</sup> Indenture of non-privileged non-rated unsecured nonconvertible debentures. This issue has a total amount of R\$150,000, with a 3-year period, semiannual repayments from the 12<sup>th</sup> month, payment of semiannual interest, and remuneration equal to CDI+ 1.4%. This funding is intended for general corporate use.

At the Board of Directors' meeting held on April 29, 2022, the creation of the Company's third Matching Shares program was approved. In relation to the previously approved programs, the following changes were made: i) reduction of the Vesting period from 4 to 3 years; and ii) release of the Vesting of the mature Matchings shares. Under the Minutes of the Board of Directors' Meeting that approved the program, the share transfer orders must be carried out throughout May 2022, due to operational issues in connection with the terms for carrying out the transfer

**Assessments and Declarations/Summary report of the Audit Committee  
(statutory, provided for in specific CVM regulations)**

The DIMED S/A DISTRIBUIDORA DE MEDICAMENTOS audit committee, in accordance with legal and statutory provisions, examined the Management Report and Financial Statements, referring to the trimester concluded in the 31st of March, 2022. Furthermore, based on the examinations performed, considering the report without any caveats by the independent auditors of Ernst & Young Auditores Independentes, dated the 11th of May, 2022, as well as any explanations gathered during the trimester, opines, by unanimity, that the referred information is adequately presented.

Eldorado do Sul, RS, 11th of May, 2022.

João Verner Juenemann  
Claudio Roberto Ely  
Nelson Bertoletti

**Assessments and Declarations/Assessment or summary report, if applicable, of the Audit committee (statutory or not)**

The DIMED S/A DISTRIBUIDORA DE MEDICAMENTOS audit committee, in accordance with legal and statutory provisions, examined the Management Report and Financial Statements, referring to the trimester concluded in the 31st of March, 2022. Furthermore, based on the examinations performed, considering the report without any caveats by the independent auditors of Ernst & Young Auditores Independentes, dated the 11th of May, 2022, as well as any explanations gathered during the trimester, opines, by unanimity, that the referred information is adequately presented.

Eldorado do Sul, RS, 11th of May, 2022.

João Verner Juenemann  
Claudio Roberto Ely  
Nelson Bertoletti

## **Reports and Representations / Officers' Representation on Quarterly Information**

In accordance with item VI of paragraph 1, article 25 of CVM Ruling No. 480 of December 7, 2009, the Executive Board's members of Dimed S.A. Distribuidora de Medicamentos, undersigned, represent that they reviewed, discussed and agreed with the information contained in the Company's Quarterly Information for the quarter ended March 31, 2022.

Eldorado do Sul, Rio Grande do Sul state, May 11, 2022.

Julio Ricardo Mottin Neto - CEO

Roberto Coimbra Santos - Executive Officer

Antônio Carlos Tocchetto Napp - Chief Investor Relations and Financial Officer

## **Reports and Representations / Officers' Representation on the Independent Auditor's Review Report**

In accordance with article 25 of CVM Ruling No. 480, the Executive Board's members of Dimed S.A. Distribuidora de Medicamentos, undersigned, represent that they reviewed, discussed and agreed with the information contained in the independent audit committee report of Ernst & Young Auditores Independentes, on Quarterly Information for the quarter ended March 31, 2022.

Eldorado do Sul, Rio Grande do Sul state, May 11, 2022.

Julio Ricardo Mottin Neto - CEO

Roberto Coimbra Santos - Executive Officer

Antônio Carlos Tocchetto Napp - Chief Investor Relations and Financial Officer

***A free translation from Portuguese into English of Independent Auditor's Review Report on individual and consolidated interim financial information prepared in Brazilian currency in accordance with NBC TG 21 – Interim Financial Reporting and IAS 34 - Interim Financial Reporting, and with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR)***

---

## **Independent auditor's review report on quarterly information**

To the  
Shareholders, Board of Directors and Officers of  
**Dimed S.A. Distribuidora de Medicamentos**  
Eldorado do Sul - RS

### **Introduction**

We have reviewed the individual and consolidated interim financial information of Dimed S.A. Distribuidora de Medicamentos (the "Company"), for the quarter ended March 31, 2022, comprising the statement of financial position as of March 31, 2022 and the related statements of profit or loss, of comprehensive income, of changes in equity and of cash flows for the three-month period then ended, including the explanatory notes.

Management is responsible for the preparation of the individual and consolidated interim financial information in accordance with NBC TG 21 – Interim Financial Reporting and IAS 34 – Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

### **Scope of review**

We conducted our review in accordance with Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion on the individual and consolidated interim financial information**

Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the quarterly information form referred to above are not prepared, in all material respects, in accordance with NBC TG 21 and IAS 34 applicable to the preparation of Quarterly Information (ITR) and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission (CVM).





## **Other matters**

### *Statements of value added*

The abovementioned quarterly information includes the individual and consolidated statement of value added (SVA) for the three-month period ended March 31, 2022, prepared under Company's Management responsibility and presented as supplementary information by IAS 34. These statements have been subject to review procedures performed together with the review of the quarterly information with the objective to conclude whether they are reconciled to the interim financial information and the accounting records, as applicable, and if its format and content are in accordance with the criteria set forth by NBC TG 09 – Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that they were not prepared, in all material respects, consistently with the overall individual and consolidated interim financial information.

Porto Alegre, May 11, 2022.

ERNST & YOUNG  
Auditores Independentes S.S.  
CRC 2SP015199/F-7

Guilherme Ghidini Neto  
Accountant CRC-RS067795/O-5